

CITATION REPORT

List of articles citing

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

DOI: 10.1182/blood-2016-08-733196
Blood, 2017, 129, 424-447.

Source: <https://exaly.com/paper-pdf/66707267/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2279	Personalisierte Medizin in der Hämatologie am Beispiel der akuten myeloischen Leukämie. 2016 , 28, 435-442		
2278	Bringing a Leukemic Stem Cell Gene Signature into Clinics: Are We There Yet?. 2017 , 20, 300-301		6
2277	Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. 2017 , 31, 185-192		42
2276	Somatic mutations characterize preleukemic stem cells in acute myeloid leukemia. <i>Blood</i> , 2017 , 129, 2587-2591	2.2	27
2275	Allogeneic transplantation in primary refractory AML. 2017 , 52, 950-951		2
2274	Recognition of familial myeloid neoplasia in adults. 2017 , 54, 60-68		28
2273	The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia. 2017 , 12, 747-753		6
2272	Combining flow cytometry and assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. 2017 , 102, e348-e351		22
2271	The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia. 2017 , 21, 583-590		17
2270	Emerging cell cycle inhibitors for acute myeloid leukemia. 2017 , 22, 137-148		8
2269	MRD in AML: a role for detecting leukemic blasts at day 14 post-induction chemotherapy?. 2017 , 58, 2521-2522		
2268	Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. 2017 , 102, 1391-1400		23
2267	NPM1 for MRD? Droplet Like It's Hot!. 2017 , 19, 498-501		5
2266	Enasidenib in mutant relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2017 , 130, 722-731	2.2	831
2265	Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. 2017 , 31, 2552-2559		13
2264	Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. 2017 , 114, E4641-E4647		25
2263	Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. 2017 , 7, e564		30

2262	Patterns of Care and Survival for Elderly Acute Myeloid Leukemia-Challenges and Opportunities. 2017 , 12, 290-299		4
2261	Diagnosis and classification of hematologic malignancies on the basis of genetics. <i>Blood</i> , 2017 , 130, 410-423		113
2260	"Chronic myelogenous leukemia in primary blast crisis" rather than "de novo -positive acute myeloid leukemia". 2017 , 5, 757-760		1
2259	Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. <i>Blood</i> , 2017 , 130, 699-712	2.2	95
2258	The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. <i>Blood</i> , 2017 , 130, 433-439	2.2	38
2257	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. <i>Blood</i> , 2017 , 130, 440-452	2.2	40
2256	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. <i>Blood</i> , 2017 , 130, 732-741	2.2	230
2255	Measurable residual disease testing in acute myeloid leukaemia. 2017 , 31, 1482-1490		132
2254	How good are we at predicting the fate of someone with acute myeloid leukaemia?. 2017 , 31, 1255-1258		21
2253	Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. 2017 , 26, 343-355		16
2252	Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. 2017 , 10, 1033-1045		12
2251	Outcome of Haploidentical SCT in Patients with Acute Leukemia. 2017 , 103-117		
2250	The progress and current status of immunotherapy in acute myeloid leukemia. 2017 , 96, 1965-1982		26
2249	Methods of Detection of Measurable Residual Disease in AML. 2017 , 12, 557-567		22
2248	Measurement of Residual Disease in Acute Myeloid Leukemia. 2017 , 12, 574-581		7
2247	Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia. 2017 , 30, 320-326		13
2246	Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). 2017 , 96, 1993-2003		79
2245	Standardy diagnostyki oraz nowe trendy w leczeniu ostrej białczki szpikowej. 2017 , 48, 291-299		

2244	Do cytogenetics affect the post-remission strategy for older patients with AML in CR1?. 2017 , 30, 306-311	5
2243	Familial myelodysplastic syndrome/acute myeloid leukemia. 2017 , 30, 287-289	14
2242	Prognostic Models in AML. 2017 , 17, S22-S23	
2241	JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia. 2017 , 77, 6627-6640	13
2240	Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia. 2017 , 102, 2039-2047	51
2239	Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit. 2017 , 62, 51-55	5
2238	Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients. 2017 , 99, 544-552	4
2237	Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. 2017 , 18, 1765-1780	57
2236	The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia. 2017 , 12, 547-556	14
2235	State of the Art Update and Next Questions: Acute Myeloid Leukemia. 2017 , 17, 703-709	6
2234	Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?. 2017 , 31, 2536-2537	10
2233	Allogeneic transplant: does age still matter?. <i>Blood</i> , 2017 , 130, 1079-1080	2.2 6
2232	Relapsed/refractory acute myeloid leukemia: any progress?. 2017 , 29, 467-473	28
2231	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. 2017 , 3, 1675-1682	78
2230	The management and treatment of acute leukemias in the elderly population. 2017 , 10, 975-985	4
2229	Mutational profiling of acute myeloid leukemia with normal cytogenetics in Brazilian patients: the value of next-generation sequencing for genomic classification. 2017 , 65, 1155-1158	9
2228	Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation. 2017 , 31, e13052	1
2227	Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients \geq 60 years. 2017 , 92, E567-E574	5

2226	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. 2017 , 123, 4430-4439	30
2225	Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia. 2017 , 56, 800-809	19
2224	Long non-coding RNAs: another brick in the wall of normal karyotype acute myeloid leukemia?. 2017 , 102, 1301-1303	3
2223	D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. 2017 , 96, 1641-1652	21
2222	The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years. 2017 , 31, 362-369	17
2221	CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?. 2017 , 10, 853-862	19
2220	Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine. 2017 , 31, 418-425	12
2219	Therapy-related myelodysplastic syndrome after successful treatment of acute promyelocytic leukemia: case report and literature review. 2017 , 25, 165-179	3
2218	Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?. 2017 , 216-217, 74-78	3
2217	Decitabine in newly diagnosed acute myeloid leukaemia: a profile of its use in the EU. 2017 , 33, 505-514	
2216	Yi-qi-yang-yin-tang increases the sensitivity of KG1a leukemia stem cells to daunorubicin by promoting cell cycle progression and regulating the expression of PTEN, TOPOII and mTOR. 2017 , 14, 6441-6448	2
2215	Improved outcome for AML patients over the years 2000-2014. 2017 , 7, 635	39
2214	How to build an allogeneic hematopoietic cell transplant unit in 2016: Proposal for a practical framework. 2017 , 65, 149-154	4
2213	Levosimendan in Cardiac Surgery. 2017 , 377, 1900	3
2212	Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. 2017 , 377, 1903	21
2211	High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. 2017 , 63, 22-27	18
2210	Haploidentical Stem Cell Transplantation. 2017 ,	1
2209	FLT3 dancing on the stem cell. 2017 , 214, 1857-1859	2

2208	History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. 2017 , 92, 1032-1036		9
2207	Akute myeloische Leukämie. 2017 , 23, 512-521		
2206	Herausforderungen in der Behandlung älterer Patienten mit akuter myeloischer Leukämie. 2017 , 23, 504-511		
2205	Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. 2017 , 23, 1736-1743		26
2204	Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers. 2017 , 14, 649-663		7
2203	How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome. 2017 , 65, 65-69		17
2202	Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. <i>Blood</i> , 2017 , 130, 946-948	2.2	31
2201	Hematopoietic stem cell transplantation: up-date from ASH 2016. 2017 , 10, 62-65		0
2200	Acute myeloid leukaemia genomics. 2017 , 179, 530-542		62
2199	Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature. 2017 , 17, 442		10
2198	Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. 2017 , 10, 124		30
2197	Hematopoietic stem cell transplantation for acute myeloid leukemia: A review. 2017 , 10, 245-251		28
2196	Allogene Transplantation in der Behandlung der akuten Leukämien. 2017 , 23, 543-549		1
2195	Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. 2017 ,		6
2194	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. 2017 ,		3
2193	Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing. 2017 , 34, 395-408		1
2192	[Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)]. 2017 , 104, S84-S98		3
2191	[Myelodysplastic syndrome, acute leukemia and stem cell transplantation]. 2017 , 76, 26-32		3

2190	Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations. 2017 , 28, 2793-2798	13
2189	Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission.. 2017 , 1, 1-13	8
2188	How and when to decide between epigenetic therapy and chemotherapy in patients with AML. 2017 , 2017, 45-53	23
2187	Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice. 2017 , 1, 1551-1564	16
2186	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. 2017 , 1, 86-89	78
2185	Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?. 2017 , 6,	24
2184	Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia. 2017 , 6,	15
2183	Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. 2017 , 8, 573	28
2182	The More, The Better: "Do the Right Thing" For Natural Killer Immunotherapy in Acute Myeloid Leukemia. 2017 , 8, 1330	14
2181	Drug Repurposing for the Treatment of Acute Myeloid Leukemia. 2017 , 4, 211	21
2180	Modeling Myeloid Malignancies Using Zebrafish. 2017 , 7, 297	12
2179	Clinical Assessment and Diagnosis of Germline Predisposition to Hematopoietic Malignancies: The University of Chicago Experience. 2017 , 5, 252	9
2178	Application of the AMLprofiler Diagnostic Microarray in the South African Setting. 2017 , 2017, 2560191	0
2177	Emerging therapies for acute myeloid leukemia: translating biology into the clinic. 2017 , 2,	21
2176	Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy. 2018 , 11, 131-155	32
2175	[Copy-number analysis identifies new prognostic marker in acute myeloid leukemia]. 2017 , 33, 929-932	
2174	Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. 2017 , 17, 852	29
2173	Highlights from the 58th meeting of the American Society of Haematology, 1-6 December 2016, San Diego, USA. 2017 , 11, 725	

2172	Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. 2017 , 2017, 37-44	30
2171	Allogeneic Hematopoietic Stem Cell Transplantation In Therapy-Related Myeloid Neoplasms (t-MN) of the Adult: Monocentric Observational Study and Review of the Literature. 2018 , 10, e2018005	7
2170	Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?. 2017 , 13, 471-480	11
2169	Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia. 2017 , 35, 2708-2715	42
2168	Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001-2013. 2018 , 139, 115-127	40
2167	Advancing a field by building consortia: The example of the European LeukemiaNet. 2018 , 124, 1100-1104	1
2166	Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. 2018 , 97, 335-342	45
2165	Development and Validation of a Novel RNA Sequencing-Based Prognostic Score for Acute Myeloid Leukemia. 2018 , 110, 1094-1101	11
2164	High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. 2018 , 180, 840-853	9
2163	Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. 2018 , 32, 1598-1608	71
2162	Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. 2018 , 32, 1338-1348	56
2161	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. 2018 , 32, 1609-1620	50
2160	Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?. 2018 , 32, 1482-1492	33
2159	Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy. 2018 , 59, 2478-2481	0
2158	Is there expert consensus on expert consensus?. 2018 , 53, 1055-1060	7
2157	Can we forecast induction failure in acute myeloid leukemia?. 2018 , 103, 375-377	4
2156	T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. 2018 , 93, 736-744	15
2155	AML refractory to primary induction with Ida-FLAG has a poor clinical outcome. 2018 , 68, 22-28	6

2154	Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. 2018 , 55, 209-214		21
2153	Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcome. 2018 , 181, 486-494		1
2152	RNA-based -ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML. <i>Blood</i> , 2018 , 131, 2485-2489	2.2	17
2151	Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. 2018 , 97, 1115-1153		55
2150	BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. 2018 , 97, 1391-1397		11
2149	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. 2018 , 24, 1615-1620		20
2148	Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing. 2018 , 39, 925-933		17
2147	Myeloid Sarcoma Predicts Superior Outcome in Pediatric AML; Can Cytogenetics Solve the Puzzle?. 2018 , 18, e249-e254		9
2146	Correlation of TET2 SNP rs2454206 with improved survival in children with acute myeloid leukemia featuring intermediate-risk cytogenetics. 2018 , 57, 379-386		6
2145	Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia. 2018 , 27, 377-387		17
2144	Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients. 2018 , 101, 86-94		19
2143	Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia. 2018 , 40, 408-418		9
2142	Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with mutation is associated with phenotypic changes and worse outcomes. 2018 , 103, e400-e403		7
2141	Germline alterations in a consecutive series of acute myeloid leukemia. 2018 , 32, 2282-2285		14
2140	Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. 2018 , 215, 1729-1747		73
2139	Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT. 2018 , 24, 1350-1359		16
2138	Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo. 2018 , 421, 112-120		21
2137	Allogeneic stem cell transplantation for mutated acute myeloid leukemia in first complete remission: does age really matter?. 2018 , 103, 191-193		1

2136	Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study. 2018 , 53, 873-879	7
2135	FLT3-ITD positive acute myeloid leukemia: A retrospective analysis of the role of allogeneic transplant and allelic ratio in patient management. 2018 , 14, 426-430	6
2134	CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia. 2018 , 14, 1147-1154	14
2133	Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial. 2018 , 93, 655-663	18
2132	A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia. 2018 , 59, 2352-2359	2
2131	Interpretation of clinical endpoints in trials of acute myeloid leukemia. 2018 , 68, 32-39	22
2130	Health Policy and Dementia. 2018 , 20, 4	5
2129	Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. 2018 , 29, 973-978	14
2128	Targeting murine leukemic stem cells by antibody functionalized mesoporous silica nanoparticles. 2018 , 8, 989	35
2127	Clinical challenges in de novo pediatric acute myeloid leukemia. 2018 , 18, 277-293	16
2126	Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission. 2018 , 107, 468-477	6
2125	ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics. 2018 , 59, 2439-2446	14
2124	Longitudinal detection of DNMT3A transcripts in patients with acute myeloid leukemia. 2018 , 93, E120-E123	6
2123	Stem Cell Transplantation for Treatment of Malignancy. 2018 , 201-214	
2122	A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. 2018 , 97, 763-772	32
2121	Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG. 2018 , 97, 977-988	10
2120	The molecular signature of AML with increased ALDH activity suggests a stem cell origin. 2018 , 59, 2201-2210	9
2119	Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. 2018 , 66, 20-27	31

2118	Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature. 2018 , 46, 317-324		7
2117	Expression of a specific extracellular matrix signature is a favorable prognostic factor in acute myeloid leukemia. 2018 , 9, 9-13		7
2116	When should patients receive consolidation chemotherapy before allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission?. 2018 , 25, 75-80		0
2115	SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders. 2018 , 11, 155-168		1
2114	Have haploidentical transplants replaced umbilical cord transplants for acute leukemias?. 2018 , 25, 103-111		13
2113	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. 2018 , 24, 956-963		12
2112	Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission. 2018 , 24, 779-788		13
2111	Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. 2018 , 103, 256-265		11
2110	A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia. 2018 , 103, 456-465		45
2109	Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. 2018 , 103, e106-e109		18
2108	A concise review of BCL-2 inhibition in acute myeloid leukemia. 2018 , 11, 145-154		14
2107	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018 , 131, 1275-1291	2.2	528
2106	Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome. 2018 , 103, 614-625		13
2105	Gene mutation patterns of Chinese acute myeloid leukemia patients by targeted next-generation sequencing and bioinformatic analysis. 2018 , 479, 25-37		6
2104	Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. 2018 , 65, 67-73		9
2103	From remission to cure: bypass or detour?. 2018 , 180, 317-318		1
2102	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. 2018 , 8, 4		21
2101	Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. 2018 , 97, 573-584		6

2100	Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice. 2018 , 9, 109-121		9
2099	Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom. 2018 , 16, 66		7
2098	Standardizing haematopoietic cell transplants in China. 2018 , 11, 34		1
2097	Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study. <i>Blood</i> , 2018 , 131, 2730-2733	2.2	4
2096	High -mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. <i>Blood</i> , 2018 , 131, 2816-2825	2.2	50
2095	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. 2018 , 32, 2352-2362		21
2094	Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group. 2018 , 2, e31		21
2093	Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults. 2018 , 24, 1621-1628		2
2092	From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia. 2018 , 18, s47-s53		4
2091	Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion. 2018 , 97, 1155-1167		9
2090	Laboratory diagnostics in hematology – new Educational Series. 2018 , 11, 81-81		
2089	Current status and trends in the diagnostics of AML and MDS. 2018 , 32, 508-519		23
2088	Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia. 2018 , 19, 865-882		11
2087	Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. <i>Blood</i> , 2018 , 132, 187-196	2.2	36
2086	Mutation of the DNMT3A and IDH1/2 genes in Iranian acute myeloid leukemia patients with normal karyotype (CN-AML): association with other gene mutation and clinical and laboratory characteristics. 2018 , 11, 29-36		1
2085	Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes. 2018 , 52, 792-800		12
2084	Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk. 2018 , 68, 72-78		6
2083	Investigational CD33-targeted therapeutics for acute myeloid leukemia. 2018 , 27, 339-348		49

2082	RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. 2018 , 32, 2189-2202			33
2081	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. 2018 , 103, 982-987			11
2080	Time to repeal and replace response criteria for acute myeloid leukemia?. 2018 , 32, 416-425			33
2079	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. 2018 , 378, 1189-1199			396
2078	Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. 2018 , 5, e161-e169			42
2077	The role of IDH mutations in acute myeloid leukemia. 2018 , 14, 979-993			57
2076	Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia. 2018 ,			19
2075	Consensus on MRD in AML?. <i>Blood</i> , 2018 , 131, 1265-1266	2.2		20
2074	Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia. 2018 , 103, e351-e355			1
2073	Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. 2018 , 103, e404-e407			131
2072	Immunobiology of Acute Leukemia. 2018 , 237-279			2
2071	Adult Stem Cells and Medicine. 2018 , 1079, 17-36			7
2070	Prognostic Prediction Model for Second Allogeneic Stem-Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single-Center Report. 2018 , 18, e167-e182			1
2069	Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary. 2018 , 24, 83-88			6
2068	Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study. 2018 , 59, 225-228			2
2067	Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived. 2018 , 59, 237-240			1
2066	A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients. 2018 , 32, 263-272			25
2065	Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. 2018 , 59, 501-504			29

2064	DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. 2018 , 32, 30-37	41
2063	Alternative splicing of hTERT: a further mechanism for the control of active hTERT in acute myeloid leukemia. 2018 , 59, 702-709	4
2062	Emerging molecular predictive and prognostic factors in acute myeloid leukemia. 2018 , 59, 2021-2039	7
2061	A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML. 2018 , 18, e13-e18	7
2060	Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. 2018 , 93, 23-30	13
2059	Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia. 2018 , 124, 286-296	20
2058	Vanin 1 (VNN1) levels predict poor outcome in acute myeloid leukemia. 2018 , 93, E4-E7	6
2057	Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT). 2018 , 93, 31-39	10
2056	Allogeneic stem cell transplantation for non-de novo AML or advanced myelodysplastic syndromes: influence of GvHD and donor lymphocyte infusions on long-term outcome. 2018 , 53, 101-103	1
2055	Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor. 2018 , 97, 51-61	11
2054	Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: Impact of T Cell-Replete Transplantation from a Haploidentical Donor. 2018 , 24, 109-118	31
2053	High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia. 2018 , 59, 114-120	5
2052	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). 2018 , 59, 1113-1120	12
2051	Determinants of 1-year survival in critically ill acute leukemia patients: a GRRR-OH study. 2018 , 59, 1323-1331	10
2050	Recommendations for reporting post-transplant relapse in AML. 2018 , 53, 111-113	1
2049	Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple alterations. 2018 , 103, e13-e16	17
2048	The importance of FLT3 mutational analysis in acute myeloid leukemia. 2018 , 59, 2273-2286	48
2047	DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML. 2018 , 59, 1938-1948	7

2046	Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. 2018 , 11, 13-24		6
2045	The impact of age, NPM1, and FLT3 allelic ratio in patients with acute myeloid leukemia. <i>Blood</i> , 2018 , 131, 1148-1153	2.2	27
2044	Chromothripsis is linked to alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype. 2018 , 103, e17-e20		31
2043	Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. 2018 , 16, 42-52		5
2042	Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. 2018 , 52, 55-62		6
2041	Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission. 2018 , 18, 106-113		2
2040	Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. 2018 , 173, 32-41		8
2039	Advances in targeted therapy for acute myeloid leukaemia. 2018 , 180, 484-500		59
2038	Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. 2018 , 14, 23-40		30
2037	Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. 2018 , 107, 138-150		39
2036	Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. 2018 , 93, 330-338		34
2035	Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome. 2018 , 53, 94-96		2
2034	Radiotherapy for extramedullary leukaemic manifestation (Chloroma). 2018 , 194, 164-173		5
2033	T-cell-replete haploidentical transplantation in acute myeloid leukemia. 2018 , 58, 5-16		3
2032	A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. 2018 , 93, 254-261		12
2031	IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma. 2018 , 17, 150-160		14
2030	Correspondence. 2018 , 55, 1005-1009		
2029	Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication?. 2018 , 36, 1463-1465		2

2028	Improving Overall Survival in Older Adults With Acute Myeloid Leukemia: Subpopulations Matter. 2018 , 36, 3186-3188	1
2027	Outcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation. 2018 , 2, 29-29	2
2026	A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. 2018 , 2, 1935-1945	17
2025	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. 2018 , 36, 3203-3210	18
2024	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. 2018 , 36, 1788-1797	111
2023	Personalisierte Medizin in der Hämatoonkologie. 2018 , 21, 49-55	
2022	Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. 2018 , 38, 555-573	44
2021	. 2018 ,	
2020	Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. 2018 , 2, 224-234	82
2019	Hyperleukozytose und Leukostase bei der akuten myeloischen Leukämie. 2018 , 21, 55-63	
2018	Universal monitoring of minimal residual disease in acute myeloid leukemia. 2018 , 3,	42
2017	Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. 2018 ,	
2016	Minimal Residual Disease in Acute Myeloid Leukemia. 2018 , 1100, 111-125	7
2015	Minimal/Measurable Residual Disease Monitoring in -Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives. 2018 , 19,	35
2014	Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. 2018 , 10,	5
2013	Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry. 2018 , 13, 455-466	10
2012	Evaluating measurable residual disease in acute myeloid leukemia. 2018 , 2, 1356-1366	87
2011	Dissecting the Immune Landscape of Acute Myeloid Leukemia. 2018 , 6,	16

2010	Molecular landscape and targeted therapy of acute myeloid leukemia. 2018 , 6, 32	20
2009	Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission. 2019 , 94, 231-239	7
2008	Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. 2018 , 19, 1668-1679	146
2007	Pre-emptive azacitidine for relapse prevention in acute myeloid leukaemia. 2018 , 19, 1557-1558	2
2006	Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. 2018 , 8, 113	66
2005	Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia. 2018 , 109, 3981-3992	6
2004	Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply. 2018 , 103, 1758-1759	4
2003	Novel Agents for Acute Myeloid Leukemia. 2018 , 10,	16
2002	Acute Myelogenous Leukemia: Diagnosis and Treatment. 2018 , 9-9	
2001	Prognostic impact of low allelic ratio ITD and mutation in acute myeloid leukemia. 2018 , 2, 2744-2754	66
2000	Clinical use of FLT3 inhibitors in acute myeloid leukemia. 2018 , 11, 7041-7052	21
1999	Hematological malignancies during pregnancy. 2019 , 10, 3-9	3
1998	Editorial. 2018 , 55, 465-468	1
1997	Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias. 2018 , 9, 5280	22
1996	Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients. 2018 , 18, 215	12
1995	Better treatment outcomes in patients with actively treated therapy-related myeloid neoplasms harboring a normal karyotype. 2018 , 13, e0209800	1
1994	A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia. 2018 , 8, 539	23
1993	Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. 2018 , 6, 33	3

1992	Nobiletin Down-Regulates c-KIT Gene Expression and Exerts Antileukemic Effects on Human Acute Myeloid Leukemia Cells. 2018 , 66, 13423-13434	10
1991	Self-nanoemulsifying system improves oral absorption and enhances anti-acute myeloid leukemia activity of berberine. 2018 , 16, 76	12
1990	Development of a safety and efficacy nanoemulsion delivery system encapsulated gambogic acid for acute myeloid leukemia in vitro and in vivo. 2018 , 125, 172-180	7
1989	Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications. 2018 , 151, 362-367	2
1988	Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. 2018 , 13, 426-434	13
1987	Significance of Cytogenetics in Leukemia Diagnostics. 2018 , 6, 165-175	1
1986	Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack. 2018 , 103, 1579-1581	1
1985	Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy. 2018 , 31, 405-409	4
1984	Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. 2018 , 32, 2546-2557	62
1983	Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. 2018 , 32, 2558-2571	11
1982	MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy. 2018 , 16, 267	10
1981	Therapy-related myeloid neoplasms: clinical perspectives. 2018 , 11, 5909-5915	9
1980	Should an HLA-matched donor still be considered the perfect donor?. 2018 , 5, e388-e390	4
1979	Human leukemia mutations corrupt but do not abrogate GATA-2 function. 2018 , 115, E10109-E10118	21
1978	S100 Proteins in Acute Myeloid Leukemia. 2018 , 20, 1175-1186	15
1977	Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. 2018 , 9, 271	32
1976	The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities. 2018 , 75, 23-28	4
1975	Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia Following Chronic Myeloproliferative Neoplasm. 2018 , 140, 231-233	4

1974	Acute myeloid leukemia: 2019 update on risk-stratification and management. 2018 , 93, 1267-1291		171
1973	Functional genomic landscape of acute myeloid leukaemia. 2018 , 562, 526-531		391
1972	Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. 2018 , 228-229, 218-235		12
1971	SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML. 2018 , 18, 769-772		14
1970	Identifying patients with genetic predisposition to acute myeloid leukemia. 2018 , 31, 373-378		15
1969	Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. 2018 , 37, 91-100		28
1968	Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis. 2018 , 75, 7-10		1
1967	Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. 2018 , 228-229, 197-217		11
1966	JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia-Response. 2018 , 78, 6342-6343		1
1965	Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance. 2018 , 19,		30
1964	Expression levels of the runt-related transcription factor 1 and 3 genes in the development of acute myeloid leukemia. 2018 , 15, 6733-6738		3
1963	The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. 2018 , 438, 63-75		73
1962	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. <i>Blood</i> , 2018 , 132, 1703-1713	2.2	142
1961	New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia. 2018 , 38, 1143-1154		12
1960	[AML in Adults - An Update on Diagnosis, Risk Classification and Therapy]. 2018 , 143, 1297-1303		1
1959	Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis. 2018 , 10,		13
1958	Priority-Lasso: a simple hierarchical approach to the prediction of clinical outcome using multi-omics data. 2018 , 19, 322		18
1957	Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. 2018 , 73, 58-66		38

1956	A new adult AML case with an extremely complex karyotype, remission and relapse combined with high hyperdiploidy of a normal chromosome set in secondary AML. 2018 , 18, 21	1
1955	Introductory Chapter: Hematology in Times of Precision and Innovation. 2018 ,	2
1954	Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. 2018 , 18, e529-e535	
1953	Measurable Residual Disease (MRD): Is it a Thing in AML?. 2018 , 18, S59-S60	
1952	Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. 2018 , 18, 814-821.e3	10
1951	Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing. 2018 , 31, 1042-1051	2
1950	Cytotoxic therapy in acute myeloid leukemia: not quite dead yet. 2018 , 2018, 51-62	7
1949	When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter. 2018 , 2018, 35-44	6
1948	Genetic heterogeneity of cytogenetically normal AML with mutations of. 2018 , 2, 2724-2731	30
1947	Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. 2018 , 2, 444-453	88
1946	Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. 2018 , 2, 1645-1650	58
1945	Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. 2018 , 2, 335-346	32
1944	acute myeloid leukemia: are we always dealing with a high-risk disease?. 2018 , 2, 1409-1411	10
1943	Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States. 2018 , 2, 1277-1282	21
1942	Recurrent mutations in -rearranged acute myeloid leukemia. 2018 , 2, 2879-2889	12
1941	When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter. 2018 , 2, 3070-3080	29
1940	Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. 2018 , 11, 549-559	42
1939	Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients. 2018 , 18, 541-547	8

1938	Quantitation of acute monocytic leukemia cells spiked in control monocytes using surface-enhanced Raman spectroscopy. 2018 , 10, 2785-2791		5
1937	Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT). 2018 , 182, 245-250		1
1936	Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation. 2018 , 24, 2337-2343		36
1935	Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia. 2018 , 16, 656-659		4
1934	Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. 2018 , 97, 1757-1765		34
1933	Next-generation sequencing for measuring minimal residual disease in AML. 2018 , 15, 473-474		4
1932	Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome. 2018 , 11, 455-461		9
1931	Shifting of erythroleukemia to myelodysplastic syndrome according to the revised WHO classification: Biologic and cytogenetic features of shifted erythroleukemia. 2018 , 70, 13-19		2
1930	How I treat older patients with acute myeloid leukemia. 2018 , 124, 2472-2483		5
1929	Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review. 2018 , 18, e303-e314		9
1928	Study of DNA methyl transferase 3A mutation in acute myeloid leukemic patients. 2018 , 19, 315-319		3
1927	The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. 2018 , 9, 163-173		33
1926	Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS. 2018 , 32, 1874-1878		6
1925	What the internist should know about stem cell transplant in the elderly patient. 2018 , 58, 43-47		
1924	Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. <i>Blood</i> , 2018 , 132, 948-961	2.2	80
1923	Germ line predisposition to myeloid malignancies appearing in adulthood. 2018 , 11, 625-636		3
1922	Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials. 2018 , 97, 1785-1795		4
1921	High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. 2018 , 8, 68		23

1920	Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia. 2018 , 8, 11293	6
1919	Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. 2018 , 7, e1472195	16
1918	Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia. 2018 , 97, 2491-2500	13
1917	Chromosome integrity checkpoints in stem and progenitor cells: transitions upon differentiation, pathogenesis, and aging. 2018 , 75, 3771-3779	13
1916	Antiproliferative effect of upregulation of hsa-let-7c-5p in human acute erythroleukemia cells. 2018 , 70, 1509-1518	7
1915	Acute myeloid leukaemia. 2018 , 392, 593-606	280
1914	Enasidenib. 2018 , 212, 187-197	1
1913	Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. 2018 , 24, 2224-2232	8
1912	Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients. 2018 , 2018, 9325261	2
1911	IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML. 2018 , 7, e1477460	6
1910	Timepoints of vancomycin-resistant Enterococcus colonization predict outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation. 2018 , 101, 620	
1909	Non-internal tandem duplication (ITD), non-tyrosine kinase domain (TKD) FLT3 mutations in myeloid malignancies: A brief report of 10 patients. 2018 , 72, 1-4	0
1908	Laminarin Promotes Immune Responses and Normalizes Glutamic Oxaloacetic Transaminase and Glutamic Pyruvic Transaminase Levels in Leukemic Mice. 2018 , 32, 783-790	9
1907	Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. 2018 , 93, 1236-1244	30
1906	Cytogenetic Profiles of 472 Indian Children with Acute Myeloid Leukemia. 2018 , 55, 469-473	1
1905	Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis. 2018 , 18, e481-e491	7
1904	Systematic review of health state utility values for acute myeloid leukemia. 2018 , 10, 83-92	16
1903	Small Molecules in Hematology. 2018 ,	4

1902	Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions. 2018 , 8, 152	22
1901	Bridging Strategies to Allogeneic Transplant for Older AML Patients. 2018 , 10,	4
1900	Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey. 2018 , 103, 2040-2048	21
1899	Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia. 2018 , 10,	13
1898	Targeting FLT3 Mutations in Acute Myeloid Leukemia. 2018 , 7,	24
1897	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. 2018 , 68, 1119-1128	54
1896	Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). 2018 , 97, 2173-2183	6
1895	Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. 2018 , 72, 20-26	23
1894	Similar survival but increased toxicity with a sequential versus concurrent FluBu4 regimen. 2018 , 53, 1221-1224	
1893	The Possible Importance of β Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia. 2018 , 19,	26
1892	Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism. 2018 , 19,	16
1891	Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach. 2018 , 10,	7
1890	Impact of blood count recovery on outcomes of acute myeloid leukemia patients achieving morphologic leukemia-free state. 2018 , 8, 53	2
1889	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. 2018 , 4, 1245-1253	53
1888	Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network. 2018 , 97, 2107-2115	2
1887	Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome. 2018 , 19,	2
1886	The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice. 2018 , 144, 1239-1251	5
1885	Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. 2018 , 8, 34	32

1884	miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia. 2018 , 8, 36		9
1883	Imiquimod inhibits growth and induces differentiation of myeloid leukemia cell lines. 2018 , 18, 15		11
1882	Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review. 2018 , 50, 959-963		
1881	mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis. <i>Blood</i> , 2018 , 131, 2266-2270	2.2	8
1880	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. 2018 , 32, 2512-2518		19
1879	Acute myeloid leukaemia: How to combine multiple tools. 2018 , 40 Suppl 1, 109-119		8
1878	Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy. 2018 , 8, 1376-1389		22
1877	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBfit). 2018 , 7, 4447-4455		13
1876	New and emerging therapies for acute myeloid leukaemia. 2018 , 66, 1088-1095		16
1875	Recent advances in the understanding and treatment of acute myeloid leukemia. 2018 , 7,		34
1874	Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. 2018 , 36, 1486-1497		94
1873	Applicability of the AML knowledge bank approach. <i>Blood</i> , 2018 , 132, 775-776	2.2	1
1872	Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis. 2018 , 10, 2635-2652		4
1871	Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study. 2018 , 18, e469-e479		8
1870	Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. <i>Blood</i> , 2018 , 132, 1604-1613	2.2	55
1869	Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse. 2018 , 18, e521-e527		7
1868	Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia. 2018 , 19, 55-74		16
1867	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. 2018 , 93, 1376-1383		8

1866	Improved Survival of Elderly-fit Patients With Acute Myeloid Leukemia Requiring Intensive Therapy: 3-Year Multicenter Analysis From TALWG. 2018 , 18, e509-e514		4
1865	Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). 2018 , 8, 76		10
1864	MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia. 2018 , 19,		48
1863	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. 2018 , 5, e411-e421		43
1862	NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. 2018 , 32, 2536-2545		22
1861	Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life. <i>Blood</i> , 2018 , 132, 865-867	2.2	11
1860	A novel type of mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia. 2018 , 103, e575-e577		7
1859	Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. 2018 , 103, 1853-1861		56
1858	Pitfalls in the molecular follow up of mutant acute myeloid leukemia. 2018 , 103, e486-e488		8
1857	Leukocytosis: Neutrophilia, Basophilia, and Blasts. 2018 , 135-170		1
1856	Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression. 2018 , 36, 576		8
1855	Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications. 2018 , 151, 362-367		10
1854	Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. 2018 , 22, 639-653		10
1853	FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia. 2018 , 18, e545-e550		13
1852	Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies. 2019 , 60, 238-241		3
1851	Impact of -ITD length on prognosis of acute myeloid leukemia. 2019 , 104, e9-e12		32
1850	Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML. 2019 , 60, 409-417		13
1849	AML: high serum ferritin at initial diagnosis has a negative impact on long-term survival. 2019 , 60, 69-77		9

1848	Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. 2019 , 33, 64-74	113
1847	End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center. 2019 , 54, 700-706	4
1846	The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know. 2019 , 56, 90-95	34
1845	Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. 2019 , 104, 113-119	132
1844	A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. 2019 , 104, 288-296	24
1843	The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. 2019 , 33, 348-357	22
1842	Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis. 2019 , 234, 1913-1924	6
1841	Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma. 2019 , 60, 3577-3580	1
1840	Chromosomal Abnormalities and Prognosis in -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. 2019 , 37, 2632-2642	40
1839	Genetic and Epigenetic Profiling in Personalized Medicine: Advances in Treatment of Acute Myeloid Leukemia. 2019 , 341-374	
1838	BCR-ABL1- and CBFβ-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis. 2019 , 98, 2461-2462	1
1837	Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia. 2019 , 187, e20-e24	2
1836	Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting. 2019 , 17, 827-839	1
1835	Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure. 2019 , 85, 106192	4
1834	A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology. 2019 , 10,	11
1833	Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. 2019 , 25, 6524-6531	5
1832	Precision medicine for TP53-mutated acute myeloid leukemia. 2019 , 4, 263-274	2
1831	Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia. 2019 , 110, 566-574	10

1830	Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1. 2019 , 7, 121-130		5
1829	Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies. 2019 , 142, 58-67		11
1828	Molecular landscape in adult acute myeloid leukemia: where we are where we going?. 2019 , 4, 17-17		1
1827	Personalized Medicine in Healthcare Systems. 2019 ,		1
1826	Genetic Testing in the Diagnosis and Biology of Acute Leukemia. 2019 , 152, 322-346		5
1825	Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. 2019 , 37, 447-455		11
1824	Maintenance therapy in AML: The past, the present and the future. 2019 , 94, 1254-1265		24
1823	Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study. 2019 , 19, 819		6
1822	Diagnose der AML und Bedeutung der MRD. 2019 , 22, 8-14		
1821	Prinzipien der AML-Therapie. 2019 , 22, 15-18		
1820	The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia. 2019 , 9, 12209		13
1819	Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. 2019 , 572, 254-259		131
1818	Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML. 2019 , 5, eaaw4304		13
1817	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <i>Blood</i> , 2019 , 134, 951-959	2.2	16
1816	A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in. 2019 , 8, 5108-5115		5
1815	Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia. 2019 , 17, 57		18
1814	Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?. 2019 , 2019, 3914828		0
1813	Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia. 2019 , 14, e0204540		5

1812	Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia. 2019 , 461, 132-143	9
1811	Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. 2019 , 10, 2040620719860645	5
1810	Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 2019 , 238, 18-22	5
1809	Korean Society for Genetic Diagnostics Guidelines for Validation of Next-Generation Sequencing-Based Somatic Variant Detection in Hematologic Malignancies. 2019 , 39, 515-523	5
1808	High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype. 2019 , 8,	16
1807	Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia. 2019 , 36, 84-99.e8	75
1806	Intelligent whole-blood imaging flow cytometry for simple, rapid, and cost-effective drug-susceptibility testing of leukemia. 2019 , 19, 2688-2698	24
1805	Nuclear factor of activated T-cells, NFATC1, governs FLT3-driven hematopoietic stem cell transformation and a poor prognosis in AML. 2019 , 12, 72	9
1804	Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia. 2019 , 125, 3121-3130	5
1803	Determining the frequency of iron overload at diagnosis in de novo acute myeloid leukemia patients with multilineage dysplasia or myelodysplasia-related changes: a case control study. 2019 , 12, 135-141	
1802	EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients. 2019 , 64, 395-401	13
1801	Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions. 2019 , 14, 386-394	12
1800	Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia. 2019 , 37, 456-463	5
1799	Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach. 2019 , 186, e223-e225	7
1798	Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. 2019 , 110, 654-664	7
1797	MRD in AML: The Role of New Techniques. 2019 , 9, 655	57
1796	Transcriptional networks in acute myeloid leukemia. 2019 , 58, 859-874	8
1795	SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation. 2019 , 187, 49-64	18

1794	-mutated relapsed or refractory AML: current challenges and future prospects. 2019 , 9, 19-32	17
1793	Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. 2019 , 141, 125-138	28
1792	Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA. 2019 , 90, 80-96	3
1791	Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness. 2019 , 10, 2891	23
1790	BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia. 2019 , 14, 68	23
1789	Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. 2019 , 94, E253-E255	26
1788	Outcomes of Autologous Hematopoietic Cell Transplantation Compared With Chemotherapy Consolidation Alone for Non-High-Risk Acute Myeloid Leukemia in First Complete Remission in a Minority-Rich Inner-City Cohort With Limited Access to Allografts. 2019 , 19, 516-521	0
1787	Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease. 2019 , 83, 106173	5
1786	How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?. 2019 , 104, 1532-1541	23
1785	Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN- γ 2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation. 2019 , 68, 1891-1899	7
1784	Clonal evolution of acute myeloid leukemia from diagnosis to relapse. 2019 , 58, 839-849	34
1783	Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study. 2019 , 11, 769-780	1
1782	Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies. 2019 , 7, 412	12
1781	A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. 2019 , 86, 106223	2
1780	Identification of STAB1 in Multiple Datasets as a Prognostic Factor for Cytogenetically Normal AML: Mechanism and Drug Indications. 2019 , 18, 476-484	8
1779	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. 2019 , 11, 141	4
1778	The implication of lncRNA expression pattern and potential function of lncRNA RP4-576H24.2 in acute myeloid leukemia. 2019 , 8, 7143-7160	6
1777	Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?. 2019 , 32, 101102	4

1776	Post-starburst galaxies in SDSS-IV MaNGA. 2019 , 489, 5709-5722	19
1775	How Do Tumor Cytogenetics Inform Cancer Treatments? Dynamic Risk Stratification and Precision Medicine Using Multi-armed Bandits. 2019 ,	1
1774	The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. 2019 , 20,	15
1773	Allogeneic transplant for - mutated AML: a focus on inhibitors before, during, and after transplant. 2019 , 10, 2040620719882666	16
1772	Establishment and characterization of a DOT1L inhibitor-sensitive human acute monocytic leukemia cell line YBT-5 with a novel KMT2A-MLLT3 fusion. 2019 , 37, 617-625	1
1771	The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?. 2019 , 14, 501-506	5
1770	Genetic variants of nucleotide excision repair pathway and outcomes of induction therapy in acute myeloid leukemia. 2019 , 16, 479-490	
1769	Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus. 2019 , 98, 2467-2483	5
1768	Assessing Measurable Residual Disease in Acute Myeloid Leukemia. 2019 , 2, 45-58	1
1767	Applications and efficiency of flow cytometry for leukemia diagnostics. 2019 , 19, 1089-1097	7
1766	Targeting Apoptotic Pathways in Acute Myeloid Leukaemia. 2019 , 11,	6
1765	The Value of FLT3, NPM1 and DNMT3A Gene Mutation Analysis in Acute Myeloid Leukemia Diagnosis. 2019 , 27, 239-243	3
1764	Myeloid Gene Panel Testing with Correlation to Updated Clinical Practice Guidelines. 2019 , 2, 65-75	
1763	Long non-coding RNA SNHG1 indicates poor prognosis and facilitates disease progression in acute myeloid leukemia. 2019 , 8,	7
1762	The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. 2019 , 9, 1162	11
1761	[What is recommended in the treatment of acute myeloid leukemia?]. 2019 , 60, 1240-1250	
1760	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. 2019 , 6, e480-e488	55
1759	Molecular diagnostics and risk assessment in myeloid malignancies. 2019 , 49-58	

1758	Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia. 2019 , 11,	8
1757	Human-level recognition of blast cells in acute myeloid leukaemia with convolutional neural networks. 2019 , 1, 538-544	54
1756	Recent Progress on Circular RNA Research in Acute Myeloid Leukemia. 2019 , 9, 1108	35
1755	Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. 2019 , 9, 1004	13
1754	Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia. 2019 , 11,	9
1753	Long Noncoding RNAs in Acute Myeloid Leukemia: Functional Characterization and Clinical Relevance. 2019 , 11,	31
1752	Detection and Quantification of FLT3 Internal Tandem Duplication Mutations Do Not Vary Significantly Between Whole Blood and Blast-Enriched Samples. 2020 , 153, 251-257	
1751	Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. 2019 , 11, 8817-8828	11
1750	DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia. 2019 , 8, 6393-6402	2
1749	Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. 2019 , 10, 2040620719882822	29
1748	Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis. 2019 , 98, 753-762	4
1747	Is post-transplant cyclophosphamide a true game-changer in allogeneic transplantation: The struggle to unlearn. 2019 , 32, 101112	
1746	Proteomic Profiling of Primary Human Acute Myeloid Leukemia Cells Does Not Reflect Their Constitutive Release of Soluble Mediators. 2018 , 7,	6
1745	Isoliquiritigenin, an Orally Available Natural FLT3 Inhibitor from Licorice, Exhibits Selective Anti-Acute Myeloid Leukemia Efficacy In Vitro and In Vivo. 2019 , 96, 589-599	2
1744	Comprehensive prognostic scoring systems could improve the prognosis of adult acute myeloid leukemia patients. 2019 , 110, 575-583	3
1743	A personalized approach to acute myeloid leukemia therapy: current options. 2019 , 12, 167-179	5
1742	Multi-study reanalysis of 2,213 acute myeloid leukemia patients reveals age- and sex-dependent gene expression signatures. 2019 , 9, 12413	3
1741	An evaluation of enasidenib for the treatment of acute myeloid leukemia. 2019 , 20, 1935-1942	3

1740	Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. 2019 , 103, 510-518		10
1739	Acute myeloid leukemia presenting as bilateral adrenal hemorrhage. 2019 , 98, 2421-2423		1
1738	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2019 , 134, 935-945	2.2	65
1737	Clinician-friendly reports of molecular measurable residual disease monitoring in acute promyelocytic leukemia. 2019 , 98, 2347-2355		0
1736	Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment. 2019 , 103, 483-490		4
1735	Trisomy 8 in acute myeloid leukemia. 2019 , 12, 947-958		13
1734	Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study. 2019 , 110, 665-674		8
1733	Analysis of the Mechanisms of Action of Naphthoquinone-Based Anti-Acute Myeloid Leukemia Chemotherapeutics. 2019 , 24,		7
1732	Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis. 2019 , 98, 2485-2496		9
1731	Hematological malignancies and molecular targeting therapy. 2019 , 862, 172641		18
1730	Acute Myeloid and Lymphoblastic Leukemia Cell Interactions with Endothelial Selectins: Critical Role of PSGL-1, CD44 and CD43. 2019 , 11,		15
1729	Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats. 2019 , 8,		26
1728	High-dose etoposide and cyclophosphamide in adults and children with primary refractory and multiply relapsed acute leukaemias: The Royal Marsden experience. 2019 , 85, 106217		3
1727	Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications. 2019 , 9, 824		10
1726	Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells. 2019 ,		2
1725	GATA2 mutations and overexpression in pediatric acute myeloid leukemia. 2019 , 4, 56-63		1
1724	Immunophenotyping. 2019 ,		0
1723	Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study. 2019 , 98, 2711-2717		10

1722	Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms. 2019 , 11,		17
1721	Prognostic Value of mRNA Expression of MAP4K Family in Acute Myeloid Leukemia. 2019 , 18, 1533033819873927		
1720	Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. 2019 , 15, 3531-3545		27
1719	CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. 2019 , 11,		61
1718	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. <i>Blood</i> , 2019 , 134, 1608-1618	2.2	45
1717	MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia. 2019 , 9, 1058		3
1716	Targeted in-vitro-stimulation reveals highly proliferative multi-virus-specific human central memory T cells as candidates for prophylactic T cell therapy. 2019 , 14, e0223258		3
1715	Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with Positive Acute Myeloid Leukemia. 2019 , 11,		16
1714	Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. <i>Blood</i> , 2019 , 134, 1558-1561	2.2	21
1713	Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia. 2019 , 19, e633-e635		
1712	The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. 2019 , 98, 541-559		22
1711	Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients. 2019 , 40, 240-250		17
1710	Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review. 2019 , 11, 87-98		8
1709	Outcome of allografting for AML-CR2 is equivalent across BSBMT and EBMT and is associated with encouraging OS and DFS across all age groups. 2019 , 54, 1151-1154		
1708	European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. 2019 , 33, 1851-1867		49
1707	Selection of three miRNA signatures with prognostic value in non-M3 acute myeloid leukemia. 2019 , 19, 109		5
1706	Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature. 2019 , 46, 2003-2011		2
1705	Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML. 2019 , 102, 368-374		3

1704	EomesT-bet CD8 T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia. 2019 , 79, 1635-1645		27
1703	Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response. 2018 , 8, 669		13
1702	Genetics of MDS. <i>Blood</i> , 2019 , 133, 1049-1059	2.2	118
1701	Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid Leukemia. 2019 , 19, e205-e212		2
1700	New study-designs to address the clinical complexity of acute myeloid leukemia. 2019 , 33, 567-569		3
1699	Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. 2019 , 12, 197-218		6
1698	Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors. 2019 , 19, 273-286		16
1697	The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome. 2019 , 11,		12
1696	Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients-a real-world experience from India. 2019 , 98, 881-888		5
1695	Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab. 2019 , 25, 1331-1339		11
1694	Acute myeloid leukemia with central diabetes insipidus. 2019 , 76, 45-52		7
1693	A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent. 2019 , 78, 45-51		9
1692	Myeloid malignancies with somatic mutations can be associated with an immunodeficiency phenotype. 2019 , 60, 2025-2033		8
1691	Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. 2019 , 9, 417		126
1690	Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. 2019 , 82, 19-23		
1689	Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. 2019 , 14, 3-17		14
1688	Acute myeloid leukemia patient with and double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis. 2019 , 11, 4129-4142		10
1687	Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. 2019 , 94, 902-912		38

1686	Stem Cells Heterogeneity in Cancer. 2019 ,	1
1685	Venetoclax-based therapies for acute myeloid leukemia. 2019 , 32, 145-153	54
1684	FLT3 overexpression in acute leukaemias: New insights into the search for molecular mechanisms. 2019 , 1872, 80-88	5
1683	Precision Medicine in Cancer Therapy. 2019 ,	1
1682	Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS. 2019 , 110, 347-354	3
1681	DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern. 2019 , 33, 2741-2746	11
1680	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. 2019 , 33, 1835-1850	50
1679	Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia. 2019 , 98, 2179-2186	3
1678	Genomics-Enabled Precision Medicine for Cancer. 2019 , 178, 137-169	6
1677	Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study. 2019 , 187, 65-72	2
1676	Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients. 2019 , 103, 208-214	8
1675	Message from the void: MRD analysis from ctDNA. <i>Blood</i> , 2019 , 133, 2631-2633	2.2 1
1674	Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. 2019 , 125, 3566-3573	12
1673	T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. 2019 , 25, 1064-1072	131
1672	Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. 2019 , 19, 617	27
1671	The Role of Forkhead Box Proteins in Acute Myeloid Leukemia. 2019 , 11,	9
1670	Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. 2019 , 4, 20	26
1669	SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness. 2019 , 9, 9139	22

1668	Acute Myeloid Leukemia Mutations: Therapeutic Implications. 2019 , 20,	11
1667	Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience. 2019 , 8, 3846-3854	9
1666	WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates. 2019 , 25, 1925-1932	18
1665	High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia. 2019 , 17, 191	10
1664	The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. 2019 , 33, 2830-2841	19
1663	Six1 regulates leukemia stem cell maintenance in acute myeloid leukemia. 2019 , 110, 2200-2210	11
1662	Strategies for minimal residual disease detection: current perspectives. 2019 , 9, 1-8	2
1661	Acute myeloid leukemia drug development in the post-venetoclax era. 2019 , 94, 959-962	4
1660	Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance. 2019 , 1139, 153-169	9
1659	Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia-Real-World Context. 2019 , 9, 450	6
1658	MicroRNA-425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy. 2019 , 17, 5793-5802	4
1657	The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML. 2019 , 94, 913-920	19
1656	Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. 2019 , 25, 1803-1809	11
1655	A novel specific cleavage of IBB protein in acute myeloid leukemia cells involves protease PR3. 2019 , 382, 111441	1
1654	High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. 2019 , 94, 921-928	18
1653	Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia. 2019 , 110, 205-212	4
1652	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. 2019 , 19, e400-e405	3
1651	Investigation of screening method for DNMT3A mutations by high-resolution melting analysis in acute myeloid leukemia. 2019 , 41, 593-600	3

1650	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. 2019 , 20, 984-997	182
1649	Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use. 2019 , 140, 1-7	16
1648	Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. 2019 , 18, 1451-1459	3
1647	Genomic profiling and predicting treatment response in acute myeloid leukemia. 2019 , 20, 467-470	7
1646	Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. 2019 , 98, 1927-1932	33
1645	Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting. 2019 , 25, 1770-1778	13
1644	Acute Myeloid Leukemia in Young Adults: Does Everyone Need a Transplant?. 2019 , 15, 315-320	2
1643	-mutated acute myeloid leukemia: comparison of next-generation sequencing (NGS) and single nucleotide polymorphism array (SNPa) findings between two cases. 2019 , 9, e2018084	2
1642	Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. 2019 , 94, 984-991	22
1641	Healthcare expenses for treatment of acute myeloid leukemia. 2019 , 12, 641-650	9
1640	Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation. 2019 , 98, 2073-2080	1
1639	Cytomegalovirus DNAemia in patients with acute myeloid leukemia undergoing cytotoxic chemotherapy. 2019 , 60, 3081-3083	
1638	Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. 2019 , 145, 1729-1749	5
1637	Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01. 2019 , 24, 893-898	6
1636	Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis. 2019 , 82, 36-42	15
1635	MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). 2019 , 12, 2903-2910	34
1634	Overexpression of PRDM5 promotes acute myeloid leukemia cell proliferation and migration by activating the JNK pathway. 2019 , 8, 3905-3917	5
1633	Healthcare expenditures of older patients with AML are similar between HMA and intensive induction chemotherapy. 2019 , 60, 2817-2820	

1632	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. 2019 , 33, 2599-2609	36
1631	Inherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia. 2019 , 41 Suppl 1, 131-141	29
1630	More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. 2019 , 39, 421-432	18
1629	How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy. 2019 , 39, 411-420	9
1628	Identification of enhancer of mRNA decapping 4 as a novel fusion partner of in acute myeloid leukemia. 2019 , 3, 761-765	1
1627	Heterogeneity in refractory acute myeloid leukemia. 2019 , 116, 10494-10503	22
1626	Do we still need morphologic evaluation in new era of advanced minimal residual disease analyses?. 2019 , 41, e145-e147	
1625	Pertussis prognostic parameters. 2019 , 51, S124-S125	
1624	High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. 2019 , 11, 3053-3060	1
1623	Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification. 2019 , 5, 1062-1064	8
1622	Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. 2019 , 19, 509-515.e1	8
1621	Genomic testing in myeloid malignancy. 2019 , 41 Suppl 1, 117-125	5
1620	Novel monoclonal antibody-based therapies for acute myeloid leukemia. 2019 , 32, 116-126	10
1619	Current status and new treatment approaches in TP53 mutated AML. 2019 , 32, 134-144	32
1618	Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?. 2019 , 20,	21
1617	Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?. 2019 , 14, 171-178	11
1616	Can we incorporate MRD assessment into clinical practice in AML?. 2019 , 32, 186-191	14
1615	Cytogenetics and associated mutation profile in patients with acute monocytic leukemia. 2019 , 41, 485-492	8

1614	Downregulation of CD73 associates with T cell exhaustion in AML patients. 2019 , 12, 40	12
1613	DNMT Inhibitors Increase Methylation in the Cancer Genome. 2019 , 10, 385	36
1612	Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy. 2019 , 19, 358	12
1611	Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia - a single center analysis. 2019 , 14, e0215453	9
1610	Nucleophosmin in leukemia: Consequences of anchor loss. 2019 , 111, 52-62	6
1609	Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia. 2019 , 9, 6083	18
1608	A strategy of Day14 bone marrows and early intervention is not superior to a strategy of noDay14 bone marrows and delayed intervention in patients with acute myeloid leukemia. 2019 , 60, 1749-1757	
1607	Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. 2019 , 36, 70-87	212
1606	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. 2019 , 10, 2031	63
1605	Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy. 2019 , 60, 2733-2743	12
1604	FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?. 2019 , 37, 1604-1607	19
1603	Isolated Bone Marrow Non-Langerhans Cell Histiocytosis Preceding RUNX1-Mutated Acute Myeloid Leukemia: Case Report and Literature Review. 2019 , 151, 638-646	2
1602	High expression of SLC38A1 predicts poor prognosis in patients with de novo acute myeloid leukemia. 2019 , 234, 20322-20328	12
1601	High expression of miR-338 is associated with poor prognosis in acute myeloid leukemia undergoing chemotherapy. 2019 , 234, 20704-20712	6
1600	The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients. 2019 , 19, 83	3
1599	Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience. 2019 , 11,	12
1598	New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise. 2019 , 20,	54
1597	Molecular Genetic Characterization of Acute Myeloid Leukemia With Trisomy 4 as the Sole Chromosome Abnormality. 2019 , 16, 175-178	0

1596	Clinical value of molecular MRD monitoring by next-generation sequencing in patients with mutated AML. 2019 , 60, 2588-2590	0
1595	The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis. 2019 , 19, 389	15
1594	Monocytes-neutrophils-ratio as predictive marker for failure of first induction therapy in AML. 2019 , 77, 103-108	1
1593	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. 2019 , 167, 133-148	14
1592	Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation. 2019 , 14, e0213739	6
1591	Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations. 2019 , 94, 650-657	20
1590	Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. 2019 , 138, 6-13	8
1589	Identification of chromosomal abnormalities and genomic features in near-triploidy/tetraploidy-acute leukemia by fluorescence in situ hybridization. 2019 , 11, 1559-1567	2
1588	Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged \geq 70 years. 2019 , 12, 105-109	3
1587	Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. 2019 , 33, 1944-1952	15
1586	Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01. 2019 , 66, e27701	6
1585	NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML. <i>Blood</i> , 2019 , 133, 2305-2319	20
1584	Emerging Therapies for Acute Myelogenous Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. 2019 , 11,	16
1583	Immunophenotypic Features of Myeloid Neoplasms Associated with Chromosome 7 Abnormalities. 2019 , 96, 300-309	4
1582	A novel flow cytometric method for enhancing acute promyelocytic leukemia screening by multidimensional dot-plots. 2019 , 98, 1413-1420	5
1581	Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. 2019 , 19, 365-371	1
1580	Clinicopathological and molecular characteristics of extramedullary acute myeloid leukaemia. 2019 , 75, 185-192	15
1579	A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia. 2019 , 15, 1895-1909	6

1578	Measurable residual disease testing for personalized treatment of acute myeloid leukemia. 2019 , 127, 337-351	6
1577	Wheat Germ Agglutinin as a Potential Therapeutic Agent for Leukemia. 2019 , 9, 100	18
1576	New drugs creating new challenges in acute myeloid leukemia. 2019 , 58, 903-914	27
1575	Meningitis in a patient with neutropenia due to <i>Rothia mucilaginosa</i> : a case report. 2019 , 13, 84	6
1574	Differences in Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia. 2019 , 11, e2019016	3
1573	Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia. 2019 , 20, 28	2
1572	Prognostic and Therapeutic Value of Day 14 Bone Marrow Aspiration in Adult Acute Myeloid Leukemia Patients. 2019 , 19, e406-e413	1
1571	Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. 2019 , 104, e555-e557	3
1570	Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. 2019 , 19, e343-e348	2
1569	Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients. 2019 , 80, 33-39	5
1568	Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients. 2019 , 186, 300-310	4
1567	DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations. 2019 , 25, 43-51	4
1566	Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. 2019 , 83, 1105-1112	7
1565	Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction. 2019 , 104, e510-e513	2
1564	Quizartinib (AC220): a promising option for acute myeloid leukemia. 2019 , 13, 1117-1125	19
1563	Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation. 2019 , 104, 2215-2224	6
1562	Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling. 2019 , 75, 52-61	16
1561	Akute myeloische Leukämie bei Erwachsenen [Ein Update zu Diagnostik, Risikoklassifikation und Therapie. 2019 , 40, 37-42	

1560	Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF- κ B-dependent P-glycoprotein upregulation. 2019 , 60, 1078-1086		20
1559	Genomic subtyping and therapeutic targeting of acute erythroleukemia. 2019 , 51, 694-704		54
1558	Ring sideroblasts in chronic phase of polycythemia vera identifies a subset of patients with an increased risk of progression to blast phase. 2019 , 40, 45-48		1
1557	Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. 2019 , 104, 868-871		24
1556	Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies. 2019 , 98, 1225-1235		13
1555	Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. 2019 , 36, 23-31		2
1554	An Unusual Cause of Epistaxis: Paranasal Sinus Myeloid Sarcoma. 2019 , 2019, 1312630		0
1553	Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS. <i>Blood</i> , 2019 , 133, 2682-2695	2.2	34
1552	Induction therapy in acute myeloid leukemia: Is it time to put aside standard 3+7?. 2019 , 37, 558-563		7
1551	Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation. 2019 , 60, 2449-2456		8
1550	High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia. 2019 , 17, 106		5
1549	Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. 2019 , 94, 803-811		23
1548	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. 2019 , 54, 1525-1552		128
1547	Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline. 2019 , 37, 239-253		10
1546	Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia. 2019 , 19, 290-299.e3		2
1545	Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?. 2019 , 11,		28
1544	FLT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy. 2019 , 67-88		0
1543	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019 , 133, 1630-1643	2.2	219

1542	Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?. 2019 , 32, 104-113	3
1541	Epigenetic therapy combinations in acute myeloid leukemia: what are the options?. 2019 , 10, 2040620718816698	6
1540	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. 2019 , 33, 1620-1634	30
1539	Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia. 2019 , 8, 3	14
1538	Different prognostic effects of core-binding factor positive AML with Korean AML registry data. 2019 , 98, 1135-1147	7
1537	Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance. 2019 , 94, 528-538	11
1536	Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine. 2019 , 33, 1923-1933	5
1535	Non-acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17). 2019 , 7, 558-563	1
1534	CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells. 2019 , 8, 1279-1288	16
1533	Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia. 2019 , 20, 15	10
1532	Progress in the problem of relapsed or refractory acute myeloid leukemia. 2019 , 26, 88-95	13
1531	In-silico comparison of two induction regimens (7 + 3 vs 7 + 3 plus additional bone marrow evaluation) in acute myeloid leukemia treatment. 2019 , 13, 18	4
1530	Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. 2019 , 104, 1798-1803	4
1529	Autologous hematopoietic cell transplantation for AML in first remission - An abandoned practice or promising approach?. 2019 , 56, 139-146	3
1528	Shifting paradigms in the treatment of older adults with AML. 2019 , 56, 110-117	9
1527	Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. 2019 , 10, 2040620719827310	63
1526	Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. 2019 , 54, 1518-1520	13
1525	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. 2019 , 54, 1511-1514	1

1524	Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia. 2019 , 11,	34
1523	Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations. 2019 , 60, 2181-2189 ⁹	
1522	Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases. 2019 , 28, 337-349	9
1521	In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. 2019 , 11, e2019001	30
1520	Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. 2019 , 35, 369-384.e7	110
1519	What is leukemia?. 2019 ,	
1518	Etoposide combined with ruxolitinib for refractory hemophagocytic lymphohistiocytosis during pregnancy: a case report and literature review. 2019 , 24, 751-756	1
1517	Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. 2019 , 3, 1939-1949	39
1516	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. 2019 , 139-158	0
1515	MRD evaluation of AML in clinical practice: are we there yet?. 2019 , 2019, 557-569	17
1514	Introductory Chapter: Germline Mutations Associated with Leukaemia - Different Genetic Landscape and Therapeutic Strategies. 2019 ,	
1513	¿Qué es la leucemia?. 2019 ,	
1512	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. 2019 , 3, 1103-1117	11
1511	Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. 2019 , 3, 3052-3061	8
1510	The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia. 2019 , 24, e171-e179	8
1509	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. 2019 , 3, 3674-3687	23
1508	A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study. 2019 , 3, 1330-1346	22
1507	Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. 2019 , 3, 2911-2919	60

1506	Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. 2019 , 3, 2454-2464	6
1505	Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome. 2019 , 3, 3322-3332	10
1504	BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. 2019 , 3, 3740-3749	5
1503	Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. 2019 , 3, 552-563	14
1502	CEBPA-mutáció vizsgálati a prognosztikai jelentőség akut myeloid leukémiában. 2019 , 52, 11-17	
1501	Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up. 2019 , 3, e321	18
1500	Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. 2019 , 3, 2608-2616	7
1499	Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern. 2019 , 3, 3111-3122	1
1498	When should transplant physicians think about familial blood cancers?. 2019 , 2, e68	1
1497	Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia. 2019 , 12, 671-686	4
1496	The Graft-Versus-Leukemia Effect in AML. 2019 , 9, 1217	23
1495	RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis. 2019 , 20,	2
1494	The Value of Adding Surveillance Cultures to Fluoroquinolone Prophylaxis in the Management of Multiresistant Gram Negative Bacterial Infections in Acute Myeloid Leukemia. 2019 , 8,	2
1493	Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia. 2019 , 19, 729-734	3
1492	Favorable long-term survival using consolidation chemotherapy without allogeneic hematopoietic cell transplantation for acute myeloid leukemia with wild-type without -ITD. 2019 , 54, 189-197	
1491	Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis. 2019 , 23, 599-608	1
1490	Introducing the HemaSphere Controversies Series. 2019 , 3, e296	0
1489	What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?. 2019 , 14, 477-479	4

1488	Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML. 2019 , 11, 1583-1600	3
1487	Intensive Chemotherapy Is Associated With Poor Overall Survival in Autoimmune Disease-associated Myeloid Malignancies. 2019 , 3, e164	
1486	The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia. 2019 , 10, 5351	38
1485	Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan. 2019 , 87, 106263	3
1484	Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain. 2019 , 11, 683-694	2
1483	The Important Role of Immunotherapies in Acute Myeloid Leukemia. 2019 , 8,	4
1482	Novel Therapies in Acute Myeloid Leukemia. 2019 , 35, 150955	6
1481	Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia. 2019 , 35, 150957	3
1480	Are we ready to use precision medicine in chronic myeloid leukemia practice?. 2019 , 104, 2327-2329	0
1479	Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients. 2019 , 3, e176	3
1478	Clinical value of new drugs in acute myeloid leukemia.. 2019 , 3,	
1477	The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis. 2019 , 98, e17406	5
1476	Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients. 2019 , 1	
1475	Application of Genomics to Clinical Practice in Haematological Malignancy. 2019 , 7, 236-252	
1474	Clinical Trials of Repurposing Medicines in Acute Myeloid Leukemia: Limitations and Possibilities in the Age of Precision Therapy. 2019 , 25, 153-163	2
1473	Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia. 2019 , 98, e15948	8
1472	Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia. 2019 , 10,	14
1471	Identification of Two Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia. 2019 , 2019, 5985923	1

1470	Prognostic Impact of Blood Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia. 2019 , 3, e167	13
1469	NGS in CML - New standard diagnostic procedure?. 2019 , 3,	1
1468	Early response evaluation in AML using mass cytometry.. 2019 , 3,	2
1467	Impact Of ELN Risk Stratification, Induction Chemotherapy Regimens And Hematopoietic Stem Cell Transplantation On Outcomes In Hyperleukocytic Acute Myeloid Leukemia With Initial White Blood Cell Count More Than 100 $\times 10^9/L$. 2019 , 11, 9495-9503	7
1466	Shifting therapeutic paradigms in induction and consolidation for older adults with acute myeloid leukemia. 2019 , 26, 51-57	4
1465	Current state of nonengrafting donor leukocyte infusion (focus on microtransplantation for acute myeloid leukemia). 2019 , 26, 373-378	2
1464	Which patients with acute myeloid leukemia in CR1 can be spared an allogeneic transplant?. 2019 , 26, 58-64	4
1463	Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. 2019 , 11,	11
1462	CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia. 2019 , 8,	6
1461	Retracted Article: Long non-coding RNA KCNQ1OT1 regulates cell proliferation, apoptosis and chemo-sensitivity through modulating the miR-186-5p/NCAM1 axis in acute myeloid leukemia cells.. 2019 , 9, 36256-36265	
1460	Germline Genetic Predisposition to Myeloid Neoplasia From Gene Mutations: Lessons Learned From Two Cases. 2019 , 3,	1
1459	Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval. 2019 , 25, 183-190	1
1458	Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBF γ MYH11 gene expression. 2019 , 98, 73-81	8
1457	What's new in consolidation therapy in AML?. 2019 , 56, 96-101	8
1456	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. 2019 , 33, 905-917	84
1455	Persistent mutations in remission can predict relapse in patients with acute myeloid leukemia. 2019 , 104, 305-311	38
1454	Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. 2019 , 62, 691-697	14
1453	Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia. 2019 , 104, 297-304	22

1452	High expression levels of SMAD3 and SMAD7 at diagnosis predict poor prognosis in acute myeloid leukemia patients undergoing chemotherapy. 2019 , 26, 119-127		6
1451	Clinical implications of molecular markers in acute myeloid leukemia. 2019 , 102, 20-35		26
1450	Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing. 2019 , 104, 277-287		20
1449	New approaches in allogeneic transplantation in AML. 2019 , 56, 147-154		5
1448	Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. 2019 , 21, 228-240		15
1447	Monitoring Minimal Residual Disease in ALL and AML. 2019 , 431-436		
1446	Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study. 2019 , 102, 341-350		9
1445	Quercetin sensitizes human myeloid leukemia KG-1 cells against TRAIL-induced apoptosis. 2019 , 234, 13233-13241		17
1444	Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome. 2019 , 116, 695-700		26
1443	Evolution of Cancer Progression in the Context of Darwinism. 2019 , 39, 1-16		13
1442	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with -ITD. <i>Blood</i> , 2019 , 133, 840-851	2.2	141
1441	Dasatinib and navitoclax act synergistically to target NUP98-NSD1/FLT3-ITD acute myeloid leukemia. 2019 , 33, 1360-1372		21
1440	NF- κ B and Poly (ADP-ribose) Polymerase 1 Form a Positive Feedback Loop that Regulates DNA Repair in Acute Myeloid Leukemia Cells. 2019 , 17, 761-772		12
1439	DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. 2019 , 131, 356-369		137
1438	Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. 2019 , 70, 97-108		2
1437	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. <i>Blood</i> , 2019 , 133, 1140-1151	2.2	61
1436	Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. 2019 , 104, 1378-1387		5
1435	Increased bone marrow CD56 natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome. 2019 , 54, 924-927		

1434	Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. 2019 , 7, 100-112	128
1433	Allogeneic hematopoietic cell transplantation; the current renaissance. 2019 , 34, 34-44	28
1432	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. 2019 , 25, 1737-1748	13
1431	Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. 2019 , 125, 712-725	33
1430	Acute myeloid leukemia in the elderly: what constitutes treatment value?. 2019 , 60, 1164-1170	3
1429	Elderly do benefit from induction chemotherapy: High dose mitoxantrone-based ("5 + 1") induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. 2019 , 94, 209-215	5
1428	Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia. 2019 , 58, 60-65	11
1427	Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. 2019 , 25, 466-473	3
1426	Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?. 2019 , 98, 561-579	4
1425	Acute Leukemia. 2019 , 343-354	
1424	A comparative evaluation of gemtuzumab ozogamicin + daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia. 2019 , 15, 663-681	3
1423	A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review. 2019 , 19, 50	11
1422	Targeting FLT3 mutations in AML: review of current knowledge and evidence. 2019 , 33, 299-312	324
1421	'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. 2019 , 74, 1062-1068	5
1420	Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years. 2019 , 98, 997-1007	9
1419	Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia. 2019 , 19, 177-182	2
1418	The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. <i>Blood</i> , 2019 , 133, 1479-1488	2.2 27
1417	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. 2019 , 25, e128-e140	24

1416	Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. 2019 , 9, 7	40
1415	Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?. 2019 , 60, 1354-1369	19
1414	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. 2019 , 33, 1124-1134	17
1413	The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia. 2019 , 33, 1700-1712	12
1412	'Looking beyond survival to define therapeutic value in acute myeloid leukemia'. 2019 , 60, 1107-1109	1
1411	The RUNX1-ETO fusion protein trans-activates c-KIT expression by recruiting histone acetyltransferase P300 on its promoter. 2019 , 286, 901-912	7
1410	Internal Tandem Duplication in Patients With Acute Myeloid Leukemia Is Readily Detectable in a Single Next-Generation Sequencing Assay Using the Pindel Algorithm. 2019 , 39, 327-329	9
1409	Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment. 2019 , 20,	56
1408	Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR. 2019 , 56, 164-170	8
1407	Haploidentical unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. 2019 , 104, 524-532	38
1406	Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. 2019 , 34, 26-33	24
1405	Acute myeloid leukemia and NK cells: two warriors confront each other. 2019 , 8, e1539617	18
1404	Apoptosis: A biomarker of high-risk phenotype in pediatric acute myeloid leukemia?. 2019 , 41, 141-147	2
1403	Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. 2019 , 285, 407-418	21
1402	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. 2019 , 33, 554-558	6
1401	Clinical implications of subclonal mutations in acute myeloid leukemia. 2019 , 104, 516-523	40
1400	Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. 2019 , 33, 371-378	6
1399	SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia. 2019 , 33, 795-799	6

1398	The emerging role of measurable residual disease detection in AML in morphologic remission. 2019 , 56, 125-130		15
1397	Predictive and Prognostic Biomarkers in Myeloid Neoplasms. 2019 , 355-362		
1396	FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation. 2019 , 25, 941-948		9
1395	Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults. 2019 , 186, 130-133		5
1394	The clinical significance of the alternative Wilms tumor gene overexpression-hypermethylation signature in acute myeloid leukemia. 2019 , 21, 864-873		1
1393	Molecular Diagnostics in Cytopathology. 2019 ,		
1392	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. 2019 , 125, 1091-1100		30
1391	Molecular remission and response patterns in patients with mutant- acute myeloid leukemia treated with enasidenib. <i>Blood</i> , 2019 , 133, 676-687	2.2	178
1390	Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation. 2019 , 54, 1189-1197		24
1389	Molecular Diagnostics in Hematologic Malignancies. 2019 , 405-424		
1388	Management of primary refractory acute myeloid leukemia in the era of targeted therapies. 2019 , 60, 583-597		3
1387	FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia. 2019 , 60, 1014-1022		10
1386	Identification of a highly lethal V3 TP53 subset in ALK lung adenocarcinoma. 2019 , 144, 190-199		41
1385	Panoramic view of common fusion genes in a large cohort of Chinese de novo acute myeloid leukemia patients. 2019 , 60, 1071-1078		11
1384	A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. 2019 , 60, 1023-1029		4
1383	Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. 2019 , 102, 87-96		23
1382	Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. 2019 , 184, 457-460		8
1381	Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients. 2020 , 105, e13-e16		10

1380	Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia. 2020 , 55, 473-475	9
1379	Loss of KDM6A confers drug resistance in acute myeloid leukemia. 2020 , 34, 50-62	34
1378	What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia?. 2020 , 55, 325-331	6
1377	Prognostic Impact of PPP2R5C Gene Expression in Adult Acute Myeloid Leukemia Patients with Normal Cytogenetics. 2020 , 36, 37-46	1
1376	Low Platelet Counts at Diagnosis Predict Better Survival for Patients with Intermediate-Risk Acute Myeloid Leukemia. 2020 , 143, 9-18	5
1375	Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC. 2020 , 105, 148-160	16
1374	Prognostic significance of PAK family kinases in acute myeloid leukemia. 2020 , 27, 30-37	9
1373	Azacytidine in Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukemia Presenting with Pneumonia: A Case Series. 2020 , 36, 377-380	
1372	Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. 2020 , 105, 1723-1730	7
1371	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. 2020 , 26, 292-299	5
1370	Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia. 2020 , 55, 452-460	9
1369	Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. 2020 , 13, 160-165	3
1368	A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients. 2020 , 22, 60-71	5
1367	Project Evaluation and Selection with Task Failures. 2020 , 29, 428-446	4
1366	Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia. 2020 , 188, 852-859	9
1365	Melt dripping behavior in the process of flame spread over energized electrical wire at different pressures. 2020 , 44, 58-64	1
1364	A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity. 2020 , 468, 1-13	12
1363	Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. 2020 , 105, 721-729	7

1362	Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patients. 2020 , 105, e157-e159	0
1361	TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment. 2020 , 105, 1306-1316	7
1360	The mutational spectrum of FLT3 gene in acute lymphoblastic leukemia is different from acute myeloid leukemia. 2020 , 27, 81-88	11
1359	Genetic characterization of ABT-199 sensitivity in human AML. 2020 , 34, 63-74	26
1358	Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia. 2020 , 27, 1-14	5
1357	MRI and PET/MRI in hematologic malignancies. 2020 , 51, 1325-1335	8
1356	Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype. 2020 , 16, 109-111	9
1355	Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. 2020 , 34, 87-99	11
1354	Intra-bone donor lymphocyte infusion at relapse: clinical outcome is associated with presence of CD8+ cells in the marrow. 2020 , 55, 974-978	
1353	Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. 2020 , 26, 197-203	7
1352	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. 2020 , 33, 334-343	6
1351	Companion gene mutations and their clinical significance in AML with double mutant CEBPA. 2020 , 27, 599-606	12
1350	Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality. 2020 , 34, 667-670	1
1349	Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. 2020 , 34, 358-368	2
1348	Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients. 2020 , 189, 153-161	4
1347	Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia. 2020 , 98, 216-225	12
1346	Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia. 2020 , 240, 15-22	5
1345	Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. 2020 , 188, 674-684	8

1344	Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3. 2020 , 126, 344-353	7
1343	The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. 2020 , 40, 100639	11
1342	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. 2020 , 7, e28-e39	40
1341	A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. 2020 , 20, 226-233.e1	7
1340	Pediatric Autoimmunity and Transplantation. 2020 ,	
1339	Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. 2020 , 55, 843-850	8
1338	Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). 2020 , 61, 588-603	0
1337	JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia. 2020 , 40, 100634	18
1336	FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia. 2020 , 188, e11-e15	14
1335	Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study. 2020 , 95, E3-E5	
1334	Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia. 2020 , 143, 438-445	0
1333	Loss of X chromosome predicts favorable prognosis in female patients with t(8;21) acute myeloid leukemia. 2020 , 61, 1168-1177	6
1332	FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. 2020 , 34, 682-696	61
1331	Is outcome of older people with acute myeloid leukemia improving with new therapeutic approaches and stem cell transplantation?. 2020 , 13, 99-108	0
1330	Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. 2020 , 34, 1563-1576	7
1329	Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?. 2020 , 34, 671-681	32
1328	Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype. 2019 , 12,	3
1327	Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia. 2020 , 61, 1158-1167	7

1326	Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial. 2020 , 21, 7	1
1325	A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. 2020 , 126, 1264-1273	11
1324	Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. 2020 , 26, 698-703	7
1323	The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia. 2020 , 43, 100650	8
1322	AML in Saudi Arabia: Analysis According to the European LeukaemiaNet 2017 Cytogenetic Classification. 2020 , 20, e212-e220	4
1321	Treatment Strategies for Therapy-related Acute Myeloid Leukemia. 2020 , 20, 147-155	3
1320	Acute Myeloid Leukemia in Mexico: The Specific Challenges of a Developing Country. Results From a Multicenter National Registry. 2020 , 20, e295-e303	4
1319	Excess burden associated with Clostridioides difficile infection in haematological patients occurring during hospitalization with induction chemotherapy in the USA. 2020 , 104, 560-566	1
1318	The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. 2020 , 95, 282-294	3
1317	Gemtuzumab Ozogamicin in -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. 2020 , 38, 623-632	35
1316	Recommendations for cytogenomic analysis of hematologic malignancies: comments from the Francophone Group of Hematological Cytogenetics (GFCH). 2020 , 34, 1711-1713	2
1315	Curcumin inhibited the growth and invasion of human monocytic leukaemia SHI-1 cells by altering MAPK and MMP signalling. 2020 , 58, 25-34	20
1314	Prevention of relapse after allogeneic stem cell transplantation in acute myeloid leukemia: Updates and challenges. 2020 , 3, e77	3
1313	Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. 2020 , 20, 377-382	5
1312	Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion Genes. 2020 , 22, 208-219	10
1311	Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study. 2020 , 61, 820-830	9
1310	Prognostic value of hypoalbuminemia at diagnosis in non-M3 acute myeloid leukemia. 2020 , 61, 641-649	3
1309	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. 2020 , 126, 765-774	34

1308	Characterization of a 4 lncRNAs-based prognostic risk scoring system in adults with acute myeloid leukemia. 2020 , 88, 106261	8
1307	Relapsed or primary refractory AML: moving past MEC and FLAG-ida. 2020 , 27, 108-114	9
1306	FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. 2020 , 111, 312-322	45
1305	Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia. 2020 , 26, 1763-1772	26
1304	A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. 2019 , 12,	9
1303	Acute Myeloid Leukemia: Aging and Epigenetics. 2019 , 12,	23
1302	Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia. 2020 , 55, 1690-1693	5
1301	Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. 2020 , 34, 1433-1443	30
1300	The face of remission induction. 2020 , 188, 101-115	2
1299	The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients. 2020 , 42, 82-87	4
1298	A 6-Membrane Protein Gene score for prognostic prediction of cytogenetically normal acute myeloid leukemia in multiple cohorts. 2020 , 11, 251-259	7
1297	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. 2020 , 34, 1701-1705	3
1296	Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia. 2020 , 24, 1-13	11
1295	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. 2020 , 7, e122-e133	11
1294	The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. 2020 , 188, 129-146	29
1293	Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia. 2020 , 188, 77-85	19
1292	The power and potential of integrated diagnostics in acute myeloid leukaemia. 2020 , 188, 36-48	21
1291	Clinical outcomes and transfusion management following intracranial hemorrhage in patients with acute leukemia. 2020 , 60, 269-274	3

1290	Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines. 2020 , 20, e76-e81	2
1289	Clonal hierarchy of main molecular lesions in acute myeloid leukaemia. 2020 , 190, 562-572	5
1288	How I investigate acute myeloid leukemia. 2020 , 42, 3-15	14
1287	Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation. 2020 , 34, 1342-1353	2
1286	Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia. 2020 , 188, 881-887	5
1285	Simple acute phase protein score to predict long-term survival in patients with acute myeloid leukemia. 2020 , 38, 74-81	4
1284	Treatment practice and outcomes in mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals. 2020 , 61, 848-854	0
1283	Detection of rare reciprocal RUNX1 rearrangements by next-generation sequencing in acute myeloid leukemia. 2020 , 59, 268-274	4
1282	RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1. 2020 , 34, 1354-1363	44
1281	Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia. 2020 , 24, 1067-1075	13
1280	EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia. 2020 , 24, 1640-1649	7
1279	Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis. 2020 , 34, 1027-1037	10
1278	Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response. 2020 , 20, e66-e75	6
1277	Genetic landscape of adult Langerhans cell histiocytosis with lung involvement. 2020 , 55,	17
1276	Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?. 2020 , 27, 81-87	3
1275	AML through the prism of molecular genetics. 2020 , 188, 49-62	7
1274	Is There Still a Role for Autologous Stem Cell Transplantation for the Treatment of Acute Myeloid Leukemia?. 2019 , 12,	6
1273	Donor KIR2DS1-Mediated Decreased Relapse and Improved Survival Depending on Remission Status at HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. 2020 , 26, 723-733	3

1272	Scalable Prediction of Acute Myeloid Leukemia Using High-Dimensional Machine Learning and Blood Transcriptomics. 2020 , 23, 100780	22
1271	The clinical mutator of core binding factor leukemia. 2020 , 34, 1553-1562	32
1270	Why classical cytogenetics still matters in acute myeloid leukemia. 2020 , 13, 95-97	3
1269	Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. 2020 , 15, e0238795	3
1268	Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible. 2020 , 10, 1746	1
1267	Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics. 2020 , 9,	4
1266	. 2020 ,	
1265	Proteostasis unbalance of nucleophosmin 1 in Acute Myeloid Leukemia: An aggregomic perspective. 2020 , 164, 3501-3507	10
1264	High CXCR2 expression predicts poor prognosis in adult patients with acute myeloid leukemia. 2020 , 11, 2040620720958586	4
1263	Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. 2020 , 4, 4623-4631	5
1262	The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives. 2020 , 21,	8
1261	Advancing leukemia diagnostics: Role of Next Generation Sequencing (NGS) in acute myeloid leukemia. 2020 , 12, 8957	3
1260	A precision medicine approach to management of acute myeloid leukemia in older adults. 2020 , 32, 650-655	1
1259	Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. 2020 , 13, 139	12
1258	Severe Acute Respiratory Syndrome Coronavirus-2 Pandemia: Facts and Perspectives in a Bone Marrow Transplant Unit. 2020 , 10, 1626	2
1257	Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. 2020 , 9,	7
1256	Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis. 2020 , 25, 356-365	2
1255	White Blood Cell Count Nadir and Duration of Aplasia Do Not Associate with Treatment Outcome in Adult Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy. 2020 , 65, 110-114	1

1254	Haploidentical Hematopoietic Stem Cell Transplantation Versus Umbilical Cord Blood Transplantation in Hematologic Malignancies: A Systematic Review and Meta-Analysis. 2020 , 29, 963689720964771	1
1253	Combined Expression of CD34 and FLT3-Internal Tandem Duplication Mutation Predicts Poor Response to Treatment in Acute Myeloid Leukemia. 2020 , 13, 867-879	1
1252	DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML. 2020 , 12,	0
1251	Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults. 2020 , 10, 104	1
1250	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. 2020 , 8,	2
1249	Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. 2020 , 38, 4163-4174	10
1248	FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome. 2020 , 10, 98	3
1247	Adherence to guidelines on nutrition support during intensive treatment of acute myeloid leukemia patients: A nationwide comparison. 2020 , 39, 242-250	5
1246	Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. 2020 , 6, 1890-1899	57
1245	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. 2020 , 13, 132	6
1244	DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets. 2020 , 12,	1
1243	Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia. 2020 , 99, 106462	2
1242	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. 2020 , 10, 96	9
1241	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. 2020 , 4, 4945-4954	13
1240	Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs. 2020 , 21,	6
1239	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. 2020 , 7, e724-e736	91
1238	Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm. 2020 , 98, 106456	13
1237	Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/. 2020 , 117, 26340-26346	14

1236	Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single-center retrospective study. 2020 , 9, 6244-6255	5
1235	Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia. 2020 , 95, 1304-1313	1
1234	Educational Updates in Hematology Book: 25th Congress of the European Hematology Association, Virtual Edition 2020. 2020 , 4, e444	1
1233	Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review. 2020 , 104, 538-545	1
1232	Mathematical Modeling Provides Evidence for Niche Competition in Human AML and Serves as a Tool to Improve Risk Stratification. 2020 , 80, 3983-3992	9
1231	Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia. 2020 , 12, 1758835920927635	1
1230	Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms. 2020 , 22, 1162-1178	6
1229	Palliative cytoreduction with low-dose intravenous melphalan in patients with acute myeloid leukemia refractory to prior treatment. 2020 , 1-6	0
1228	Inhibition of NF- κ B Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics. 2020 , 9,	1
1227	Analytical and Potential Clinical Performance of OncoPrint Myeloid Research Assay for Myeloid Neoplasms. 2020 , 24, 579-592	4
1226	Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN). 2020 , 38, 2993-3002	122
1225	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. 2020 , 34, 2780-2784	2
1224	Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. 2020 , 136, 116-129	11
1223	After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia. 2020 , 2020, 2134647	1
1222	Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. 2020 , 21,	2
1221	Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. 2020 , 4, 3840-3849	4
1220	Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments. 2020 , 9,	13
1219	Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. 2020 , 99, 106477	4

1218	Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points. 2020 , 10, 122	8
1217	Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. 2020 , 10, 596134	8
1216	Development and validation of a prognostic model for adult patients with acute myeloid leukaemia. 2020 , 62, 103126	2
1215	Mutational screening of RTK-BRAF genes in de novo adult acute myeloid leukemia. 2020 , 21, 100904	
1214	Preleukemic stem cells: leave it or not?. 2020 , 2, 54-58	0
1213	-Mutated Myeloid Neoplasms with . 2020 , 21,	8
1212	Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML. 2020 , 8, 65	0
1211	Next-generation diagnostics for precision oncology: Preanalytical considerations, technical challenges, and available technologies. 2020 ,	2
1210	Digital Polymerase Chain Reaction Paired with High-Speed Atomic Force Microscopy for Quantitation and Length Analysis of DNA Length Polymorphisms. 2020 , 14, 15385-15393	0
1209	[European approvals: Glasdegib for Acute myeloid leukemia]. 2020 , 107, 1206-1207	
1208	Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia. 2020 , 29, 387-397	1
1207	Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults . 2020 , 15, e0235503	0
1206	Treating acute myeloid leukemia in the modern era: A primer. 2020 , 126, 4668-4677	12
1205	Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. 2020 , 21, 1201-1212	75
1204	Machine learning derived genomics driven prognostication for acute myeloid leukemia with. 2020 , 61, 3154-3160	5
1203	An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism. 2020 , 29, 973-988	3
1202	Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis. 2020 , 60, 2360-2369	13
1201	A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. 2020 , 95, 1457-1465	1

1200	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. 2020 , 383, 617-629	528
1199	Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML. 2020 , 9, 6515-6523	3
1198	Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium. 2020 , 10, 75	1
1197	Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer-What Can We Learn from the Hematological Experience?. 2020 , 12,	14
1196	Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. 2020 , 27, 81	18
1195	A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy. 2020 , 126, 4315-4321	4
1194	Management of Acute Myeloid Leukemia (AML) in Older Patients. 2020 , 22, 103	3
1193	Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. 2020 , 8,	12
1192	HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation. 2020 , 12,	3
1191	Cutting Edge Molecular Therapy for Acute Myeloid Leukemia. 2020 , 21,	4
1190	BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML. 2020 , 38, 3461-3464	1
1189	AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances. 2020 , 11,	11
1188	Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation. 2020 , 13, 959-969	
1187	Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. 2020 , 190, e48-e51	18
1186	PD-L1 Is Expressed and Promotes the Expansion of Regulatory T Cells in Acute Myeloid Leukemia. 2020 , 11, 1710	13
1185	Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci. 2020 , 33, 101191	2
1184	Socioeconomic deprivation is associated with decreased survival in patients with acute myeloid leukemia. 2020 , 66, 101699	3
1183	Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study. 2020 , 111, 3367-3378	5

1182	Clinical and molecular consequences of fusion genes in myeloid malignancies. 2020 , 38, 1366-1374	6
1181	Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation. 2020 , 20, 791-796	3
1180	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. 2020 , 34, 2903-2913	18
1179	Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome. 2020 , 117, 20117-20126	8
1178	Real-World Outcomes of Patients with Refractory or Relapsed -ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. 2020 , 12,	3
1177	Comparison of Myeloablative (CyTBI, BuCy) versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Pretransplant Low WT1 Expression. 2020 , 26, 2018-2026	5
1176	Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients. 2020 , 10, 12761	9
1175	Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy. 2020 , 42, 849-857	4
1174	Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation. 2020 , 26, 1995-2000	0
1173	Pattern and Dynamics of FLT3 Duplications. 2020 , 60, 4005-4020	4
1172	SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis. 2020 , 12,	7
1171	Marker chromosome is a strong poor prognosis factor after allogeneic HSCT for adverse-risk AML patients. 2020 , 105, 616-625	1
1170	Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. 2020 , 21,	8
1169	Leukemia stem cell gene expression signatures contribute to acute myeloid leukemia risk stratification. 2020 , 105, 533-536	0
1168	WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid Leukemia. 2020 , 20, e998-e1009	2
1167	Histamine receptor 1 is expressed in leukaemic cells and affects differentiation sensitivity. 2020 , 24, 13536-13541	
1166	Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes. 2020 , 98, 106453	4
1165	Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML. 2020 , 4, 5040-5049	2

1164	Acute myeloid leukemia-induced remodeling of the human bone marrow niche predicts clinical outcome. 2020 , 4, 5257-5268	8
1163	Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. 2020 , 4, 5322-5335	1
1162	Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. 2020 , 4, 5146-5156	2
1161	Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. 2020 , 4, 5336-5342	18
1160	Immunophenotyping in the Diagnosis and Monitoring of Haematological Neoplasms and Related Conditions with Tables and Figures for Quick Reference. 2020 , 47-87	
1159	A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia. 2020 , 10, 18514	3
1158	Risk factors and outcome of COVID-19 in patients with hematological malignancies. 2020 , 9, 21	57
1157	Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). 2020 , 154, 731-741	4
1156	Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDGAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study. 2020 , 12, 132	3
1155	Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?. 2020 , 13, 1057-1065	1
1154	LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia. 2020 , 20, 841	4
1153	A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine. 2020 , 21,	2
1152	Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique. 2020 , 9, 8457-8467	10
1151	Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. 2020 , 61, 3287-3305	2
1150	Long Non-Coding RNA Taurine Upregulated Gene 1 Targets miR-185 to Regulate Cell Proliferation and Glycolysis in Acute Myeloid Leukemia Cells in vitro. 2020 , 13, 7887-7896	4
1149	Co-delivery of homoharringtonine and doxorubicin boosts therapeutic efficacy of refractory acute myeloid leukemia. 2020 , 327, 766-778	5
1148	A single-cell survey of cellular hierarchy in acute myeloid leukemia. 2020 , 13, 128	13
1147	Noninvasive prenatal testing detected acute myeloid leukemia in paucisymptomatic pregnant patient. 2020 , 8, 1924-1927	1

1146	Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia. 2020 , 38, 754-762	3
1145	Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect MDS/AML Disease Registry. 2020 , 1, 58-68	1
1144	Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia. 2020 , 15, 681-689	2
1143	Aberrant Expression Is Associated With Adverse Outcome in Cytogenetically Normal Acute Myeloid Leukemia. 2020 , 10, 1648	3
1142	Experiences with Next-Generation Sequencing in Relapsed Acute Myeloid Leukemia: A Patient Case Series. 2020 , 12, e2020068	0
1141	Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia. 2020 , 1, 79-85	0
1140	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. 2020 , 12,	12
1139	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. 2020 , 95, 1511-1521	28
1138	Venetoclax in AML: Where We Are and Where We Are Headed. 2020 , 20 Suppl 1, S25-S26	2
1137	Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy. 2020 , 61, 3532-3533	1
1136	The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia. 2020 , 13, 394	0
1135	Characterization of FLT3-ITD acute myeloid leukemia: molecular profiling of leukemic precursor cells. 2020 , 10, 85	4
1134	Identification of Long Non-Coding RNA Family as Promising Prognostic Biomarkers in Acute Myeloid Leukemia. 2020 , 13, 8441-8450	2
1133	Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML. 2020 , 99, 2417-2427	0
1132	Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients. 2020 , 191, e120-e124	13
1131	Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML. 2020 , 10, 1934-1949	8
1130	Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation. 2020 , 4, 4430-4437	7
1129	Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia. 2020 , 99, 2939-2945	

1128	Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types. 2020 , 5, e000803	5
1127	Differential response to cytotoxic therapy explains treatment dynamics of acute myeloid leukaemia patients: insights from a mathematical modelling approach. 2020 , 17, 20200091	2
1126	Impact of Bone Marrow miR-21 Expression on Acute Myeloid Leukemia T Lymphocyte Fragility and Dysfunction. 2020 , 9,	6
1125	Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. 2020 , 4, 4267-4277	4
1124	High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG). 2020 , 12,	2
1123	Genomic Strategies for Personalized Cancer Therapy. 2020 , 1-60	
1122	Updated safety of midostaurin plus chemotherapy in newly diagnosed mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program. 2020 , 61, 3146-3153	4
1121	Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. 2020 , 4, 3864-3874	15
1120	Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation. 2020 , 12,	4
1119	Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. 2020 , 99, 2405-2416	3
1118	Higher TIGITCD226 ⁺ T cells in Patients with Acute Myeloid Leukemia. 2020 , 1-11	12
1117	AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. 2020 , 8, 29	6
1116	Evaluating ivosidenib for the treatment of acute myeloid leukemia. 2020 , 21, 2205-2213	4
1115	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. <i>Blood</i> , 2020 , 136, 3041-3050	2.2 30
1114	Acute myeloid leukemia: 2021 update on risk-stratification and management. 2020 , 95, 1368-1398	25
1113	Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia. 2020 , 1, 134-145	15
1112	Minimal Residual Disease Eradication by Azacitidine Maintenance in a Patient with Core-Binding Factor Acute Myeloid Leukemia. 2020 , 65, 166-170	1
1111	Inhibition of CSRP2 Promotes Leukemia Cell Proliferation and Correlates with Relapse in Adults with Acute Myeloid Leukemia. 2020 , 13, 12549-12560	2

1110	Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. 2020 , 5, 288	27
1109	Comprehensive assessment of TP53 loss of function using multiple combinatorial mutagenesis libraries. 2020 , 10, 20368	2
1108	RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. 2020 , 10, 20119	0
1107	Philadelphia Chromosome-positive Acute Myeloid Leukemia With e1a3 Fusion Transcript. 2020 , 4, e484	2
1106	Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents.. 2020 , 11, 2040620720966882	0
1105	Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients. 2020 , 4, 5936-5941	8
1104	Latest Implications of Next-Gen Sequencing in Diagnosis of Acute and Chronic Myeloid Leukemia. 2020 ,	
1103	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. 2020 , 4, 6342-6352	11
1102	Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond. 2020 , 10, 562219	0
1101	Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy. 2021 , 35, 2030-2042	7
1100	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. 2020 , 383, 2526-2537	100
1099	Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. 2020 , 10, 612880	24
1098	Preferential Activity of Extract on Primary Myeloid Leukemic Blast. 2020 , 2020, 4736206	0
1097	Successful treatment of de novo multiple primary malignancy with long term favorable outcome. 2020 , 2, 100030	
1096	Prognostic factors for clinical outcomes of patients with central nervous system leukemia. 2021 , 14, 240-245	
1095	Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. 2020 , 39, 278	11
1094	Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. 2020 , 10, 599933	4
1093	Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML). 2020 , 12,	2

1092	Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia. 2020 , 10,	3
1091	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. 2020 , 4, 6117-6126	14
1090	Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects. 2020 , 4, 6077-6085	18
1089	Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. 2020 , 4, 5681-5689	29
1088	Dynamical behavior of leukemic cells with chemotherapy in acute myeloid leukemia. 2020 , 1503, 012003	
1087	Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category. 2020 , 12,	1
1086	Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. 2020 , 10, 562558	15
1085	NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature. 2020 , 12, e2020083	1
1084	Characterization of somatic mutation-associated microenvironment signatures in acute myeloid leukemia patients based on TCGA analysis. 2020 , 10, 19037	3
1083	Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS. 2020 , 4, 5393-5401	9
1082	A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition. 2020 , 33, 101220	3
1081	Chronic Myeloid Leukemia in 2020. 2020 , 4, e468	21
1080	Clinical outcomes and characteristics of patients with -mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience. 2020 , 61, 2180-2190	7
1079	Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in mutant acute myeloid leukemia. 2020 , 105, e9-e12	3
1078	State-Transition Analysis of Time-Sequential Gene Expression Identifies Critical Points That Predict Development of Acute Myeloid Leukemia. 2020 , 80, 3157-3169	8
1077	Venetoclax is safe and efficacious in relapsed/refractory AML. 2020 , 61, 2221-2225	15
1076	Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFβ-MYH11. 2020 , 4, 66-75	22
1075	High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population. 2020 , 105, e507	5

1074	Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia. 2020 , 99, 1411-1413	
1073	High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission. 2020 , 55, 2207-2210	
1072	Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies. 2020 , 15, 194-202	4
1071	The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. 2020 , 95, 1006-1014	24
1070	Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. 2020 , 10, 47	9
1069	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. 2020 , 55, 2244-2253	1
1068	Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. 2020 , 4, 1894-1905	62
1067	Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia. 2020 , 8, 249	13
1066	CD34CD38CD123 Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. 2020 , 12,	4
1065	Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. 2020 , 10, 48	10
1064	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. 2020 , 4, 1942-1949	14
1063	A Novel Scoring System for Risk Assessment of Elderly Patients With Cytogenetically Normal Acute Myeloid Leukemia Based on Expression of Three AQP1 DNA Methylation-Associated Genes. 2020 , 10, 566	1
1062	Methods used in the selection of instruments for outcomes included in core outcome sets have improved since the publication of the COSMIN/COMET guideline. 2020 , 125, 64-75	11
1061	Outcome of Childhood Acute Myeloid Leukemia With FLT3-ITD Mutation: The Experience of Children's Cancer Hospital Egypt, 2007-17. 2020 , 20, e529-e541	0
1060	Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. 2020 , 22, 61	10
1059	Competing endogenous RNA regulation in hematologic malignancies. 2020 , 509, 108-116	4
1058	The increasing complexity of the management of core-binding factor acute myeloid leukemia. 2020 , 105, 1475-1477	0
1057	CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study. 2020 , 9, 5327-5334	4

1056	NPM1 Biology in Myeloid Neoplasia. 2020 , 15, 350-359		5
1055	A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study. 2020 , 10, 64		6
1054	Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 1729-1738	2.2	27
1053	Model-Based Optimal AML Consolidation Treatment. 2020 , 67, 3296-3306		2
1052	A post-stem cell transplant risk score for Philadelphia-negative acute lymphoblastic leukemia. 2020 , 105, 1177-1179		0
1051	The Influence of Methylating Mutations on Acute Myeloid Leukemia: Preliminary Analysis on 56 Patients. 2020 , 10,		2
1050	A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML. 2020 , 20, e673-e684		5
1049	RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia. 2020 , 27, 64-80.e9		88
1048	Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group. 2020 , 191, 405-417		3
1047	Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on Dendritic cells of leukemic origin (DC). 2020 , 217, 108467		3
1046	Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged . 2020 , 34, 3215-3227		24
1045	Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia. 2020 , 117, 13670-13679		10
1044	Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study. 2020 , 111, 2472-2481		1
1043	Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. 2020 , 4, 2339-2350		7
1042	The prevalence of extramedullary acute myeloid leukemia detected by FDG-PET/CT: final results from the prospective PETAML trial. 2020 , 105, 1552-1558		17
1041	Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. 2020 , 4, 2192-2201		32
1040	Hämatologische Erkrankungen. 2020 ,		1
1039	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. 2020 , 26, 1511-1519		1

1038	Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting. 2020 , 21, 437			2
1037	Advances in targeted therapy for acute myeloid leukemia. 2020 , 8, 17			17
1036	High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia. 2020 , 105, 449-459			3
1035	Comparing the area under the curve and peak height methods in the calculation of FLT3-ITD allelic ratio. 2020 , 42, e234-e236			
1034	miR-582-5p serves as an antioncogenic biomarker in intermediate risk AML with normal cytogenetics and could inhibit proliferation and induce apoptosis of leukemia cells. 2020 , 44, 2021-2030			5
1033	Novel Treatment Paradigms in Acute Myeloid Leukemia. 2020 , 108, 506-514			5
1032	Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report. 2020 , 52, 2548-2550			
1031	Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery. 2020 , 28, 2237-2251			20
1030	Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. <i>Blood</i> , 2020 , 136, 1983-1988	2.2		17
1029	Overexpression of HOXA10 is associated with unfavorable prognosis of acute myeloid leukemia. 2020 , 20, 586			10
1028	The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse. 2020 , 112, 200-209			4
1027	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. <i>Blood</i> , 2020 , 136, 823-830	2.2		35
1026	Cytogenetics in the genomic era. 2020 , 33, 101196			1
1025	FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression. 2020 , 24, 7675-7679			2
1024	Treatment of Acute Myeloid Leukemia in the Era of Genomics-Achievements and Persisting Challenges. 2020 , 11, 480			10
1023	Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm. 2020 , 34, 621-629			5
1022	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. 2020 , 34, 2914-2924			2
1021	Fc gamma receptor expression serves as prognostic and diagnostic factor in AML. 2020 , 61, 2466-2474			1

1020	Acute Myeloid Leukemia in Qatar (2010-2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes. 2020 , 11, 553	2
1019	Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia. 2020 , 12,	6
1018	Nucleophosmin 1 Mutations in Acute Myeloid Leukemia. 2020 , 11,	13
1017	Identification of the key genes and microRNAs in adult acute myeloid leukemia with FLT3 mutation by bioinformatics analysis. 2020 , 17, 1269-1280	3
1016	Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia. 2020 , 29, 102236	2
1015	Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation. 2020 , 11, 2040620720930614	6
1014	Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. 2020 , 95, 106402	5
1013	High Expression of the SH3TC2-DT/SH3TC2 Gene Pair Associated With FLT3 Mutation and Poor Survival in Acute Myeloid Leukemia: An Integrated TCGA Analysis. 2020 , 10, 829	5
1012	Impact of Covid-19 on the treatment of acute myeloid leukemia. 2020 , 34, 2254-2256	21
1011	HMG A Proteins in Hematological Malignancies. 2020 , 12,	5
1010	Association Analysis of TP53 rs1042522, MDM2 rs2279744, rs3730485, MDM4 rs4245739 Variants and Acute Myeloid Leukemia Susceptibility, Risk Stratification Scores, and Clinical Features: An Exploratory Study. 2020 , 9,	4
1009	Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going. 2020 , 9,	5
1008	Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. 2020 , 191, 52-61	12
1007	Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. 2020 , 117, 14331-14341	21
1006	How I treat relapsed or refractory AML. <i>Blood</i> , 2020 , 136, 1023-1032	2.2 22
1005	Epigenetic regulation of normal hematopoiesis and its dysregulation in hematopoietic malignancies. 2020 , 285-313	1
1004	The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. 2020 , 13, 72	55
1003	The KDM Inhibitor GSKJ4 Triggers CREB Downregulation via a Protein Kinase A and Proteasome-Dependent Mechanism in Human Acute Myeloid Leukemia Cells. 2020 , 10, 799	6

1002	The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles. 2020 , 12,	14
1001	Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. 2020 , 95, 1135	1
1000	Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. 2020 , 12,	5
999	Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation. 2020 , 112, 243-248	6
998	Is Highly Expressed and Associated With Poor Survival in Acute Myeloid Leukemia. 2020 , 10, 149	4
997	Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation. 2020 , 9, 3371-3382	4
996	Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients. 2020 , 61, 1695-1701	0
995	Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia. 2020 , 9,	13
994	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. 2020 , 105, 47-55	1
993	RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia. 2020 , 26, 3597-3607	15
992	Bone Marrow Senescence and the Microenvironment of Hematological Malignancies. 2020 , 10, 230	10
991	Recent advances in allogeneic hematopoietic cell transplantation for acute myeloid leukemia. 2020 , 27, 115-121	4
990	Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia. 2020 , 189, 815-825	9
989	The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. 2020 , 61, 2020-2023	11
988	Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia. 2020 , 12,	12
987	Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors. 2020 , 699-715	4
986	Systematic Construction and Validation of a Metabolic Risk Model for Prognostic Prediction in Acute Myelogenous Leukemia. 2020 , 10, 540	4
985	Low-intensity regimens standard-intensity induction strategies in acute myeloid leukemia. 2020 , 11, 2040620720913010	8

984	JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML). 2020 , 111, 595-613	6
983	B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles. 2020 , 10, 264	4
982	Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. 2020 , 33, 1678-1689	7
981	IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia. 2020 , 12,	22
980	Functional Classification of Mutations in Acute Myeloid Leukemia. 2020 , 12,	20
979	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine + idasanutlin in relapsed or refractory acute myeloid leukemia. 2020 , 16, 807-815	26
978	Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients. 2020 , 189, 718-730	6
977	Less Is Not Necessarily More: Toward a Rational Selection of the Conditioning Regimen in Acute Myeloid Leukemia. 2020 , 38, 1249-1251	1
976	Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?. 2020 , 34, 963-965	9
975	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. 2020 , 10, 26	14
974	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. 2020 , 34, 3149-3160	19
973	Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML. 2020 , 2020, 8021095	
972	Identification and validation of prognosis-related DLX5 methylation as an epigenetic driver in myeloid neoplasms. 2020 , 10, e29	13
971	Fertility Preservation in Oncological and Non-Oncological Diseases. 2020 ,	0
970	Acute myeloid leukemia and artificial intelligence, algorithms and new scores. 2020 , 33, 101192	6
969	Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. 2020 , 26, 1459-1467	47
968	Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling. 2020 , 95, 1148	4
967	The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C. 2020 , 13, 100780	

966	Treatment of Relapsed Acute Myeloid Leukemia. 2020 , 21, 66		39
965	A stitch in time saves nine MRD-based pre-emptive therapy. 2020 , 191, 19-20		
964	Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies. 2020 , 19, 1533033820937008		2
963	Detection of Fusion Genes to Determine Minimal Residual Disease in Leukemia Using Next-Generation Sequencing. 2020 , 66, 1084-1092		3
962	NPM1-mutated acute myeloid leukemia: from bench to bedside. <i>Blood</i> , 2020 , 136, 1707-1721	2.2	52
961	Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro. 2020 , 4, 3000-3010		10
960	Identification the prognostic value of glutathione peroxidases expression levels in acute myeloid leukemia. 2020 , 8, 678		22
959	CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF- β Signaling. 2020 , 12,		4
958	Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid Leukemia Patients. 2020 , 12,		7
957	Impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia; retrospective analysis and literature review. 2020 , 14, 100206		1
956	The natural alkaloid Jerantinine B has activity in acute myeloid leukemia cells through a mechanism involving c-Jun. 2020 , 20, 629		1
955	The molecular analysis of four coexistent mutations in additional sex combs like 1 (ASXL1) gene in a patient with acute myeloid leukemia. 2020 , 13, 165-168		1
954	Prognostic alternative mRNA splicing signatures and associated splicing factors in acute myeloid leukemia. 2020 , 22, 447-457		5
953	Outcomes of symptomatic venous thromboembolism after haploidentical donor hematopoietic stem cell transplantation and comparison with human leukocyte antigen-identical sibling transplantation. 2020 , 194, 168-175		0
952	Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. <i>Blood</i> , 2020 , 136, 2442-2456	2.2	27
951	A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia. 2020 , 98, 1069-1091		33
950	Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. 2020 , 40, 3883-3888		0
949	Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. 2020 , 95, 1193		13

948	COVID-19 lockdown and mental health: why we must look into oncology units. 2020 , 1-2	2
947	Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia. 2020 , 99, 2173-2180	4
946	More than ten percent of relapses occur after five years in AML patients with mutation. 2020 , 61, 1226-1229	3
945	Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: an analysis based on TCGA database. 2020 , 25, 79-84	6
944	DNA methylation-mediated Siglec-7 regulation in natural killer cells via two 5' promoter CpG sites. 2020 , 160, 38-51	2
943	The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia. 2020 , 9, 1572-1580	8
942	Venetoclax in acute myeloid leukemia - current and future directions. 2020 , 61, 1313-1322	14
941	An evaluation of glasdegib for the treatment of acute myelogenous leukemia. 2020 , 21, 523-530	9
940	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. 2020 , 12,	7
939	Integrin β 7 and Extracellular Matrix Laminin 211 Interaction Promotes Proliferation of Acute Myeloid Leukemia Cells and Is Associated with Granulocytic Sarcoma. 2020 , 12,	12
938	Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?. 2020 , 9,	8
937	Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated versus acute myeloid leukemia with myelodysplasia-related changes with mutated. 2020 , 61, 1395-1405	3
936	Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. 2020 , 190, 533-544	7
935	Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia. 2020 , 12,	5
934	Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. 2020 , 126, 2183-2192	8
933	The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. 2020 , 11, 1044	31
932	Driver mutations in acute myeloid leukemia. 2020 , 27, 49-57	16
931	Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). 2020 , 190, 274-283	4

930	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. 2020 , 61, 1220-1225	8
929	AML: New Drugs but New Challenges. 2020 , 20, 341-350	9
928	Genome-wide identification of FHL1 as a powerful prognostic candidate and potential therapeutic target in acute myeloid leukaemia. 2020 , 52, 102664	9
927	Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity. 2020 , 189, 672-683	3
926	Drug-Related Carcinogenesis: Risk Factors and Approaches for Its Prevention. 2020 , 85, S79-S107	5
925	Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. 2020 , 126, 1837-1855	11
924	Outcomes of Older Patients with Mutated and -ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation. 2020 , 4, e326	5
923	Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia. 2020 , 11, 2040620719899818	15
922	Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome. 2020 , 99, 773-780	6
921	Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics. 2020 , 27, 66-75	4
920	The clinical and prognostic significance of FOXN3 downregulation in acute myeloid leukaemia. 2020 , 42, 270-276	2
919	How I treat newly diagnosed acute myeloid leukemia in an outpatient setting: a multidisciplinary team perspective. 2020 , 16, 281-291	3
918	Unique morphologic and genetic characteristics of acute myeloid leukemia with chromothripsis: a clinicopathologic study from a single institution. 2020 , 98, 22-31	6
917	Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm. 2020 , 61, 1728-1731	0
916	Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. 2020 , 91, 106339	8
915	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. 2020 , 95, 612-622	20
914	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. 2020 , 126, 2193-2205	17
913	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. 2020 , 26, 1160-1170	4

912	Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers. 2020 , 21,	5
911	Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'. 2020 , 61, 1445-1454	2
910	Screening the Cancer Genome Atlas Database for Genes of Prognostic Value in Acute Myeloid Leukemia. 2019 , 9, 1509	13
909	Clonal competition within complex evolutionary hierarchies shapes AML over time. 2020 , 11, 579	10
908	Archived bone marrow smears are an excellent source for NGS-based mutation detection in acute myeloid leukemia. 2020 , 34, 2220-2224	1
907	Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. 2020 , 33, 1380-1388	4
906	Identification of CD318 (CDCP1) as novel prognostic marker in AML. 2020 , 99, 477-486	8
905	A heavy metal baseline score predicts outcome in acute myeloid leukemia. 2020 , 95, 422-434	6
904	Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective. 2020 , 17, 1-10	9
903	Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date. 2020 , 12, 151-163	11
902	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. 2020 , 34, 1577-1587	10
901	Highly Sensitive Detection of Mutations in Acute Myeloid Leukemia. 2020 , 9,	6
900	Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience. 2020 , 90, 106314	28
899	Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. 2020 , 10, 536-551	93
898	Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. 2020 , 13, 8	11
897	Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. 2020 , 16, e464-e475	4
896	Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. 2020 , 99, 501-511	28
895	Improved survival of AML patients by addition of cladribine to standard induction chemotherapy. 2020 , 99, 519-525	3

894	Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. 2020 , 9, 2	28
893	The differential activation of metabolic pathways in leukemic cells depending on their genotype and micro-environmental stress. 2020 , 16, 13	4
892	Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia. 2020 , 10, 1	13
891	Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia. 2020 , 185, 299-306	6
890	Serum levels of selected cytokines and soluble adhesion molecules in acute myeloid leukemia: Soluble receptor for interleukin-2 predicts overall survival. 2020 , 128, 155005	1
889	Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. 2020 , 34, 1751-1759	11
888	Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. 2020 , 10, 506-525	96
887	Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'. 2020 , 90, 106300	4
886	AMLVaran: a software approach to implement variant analysis of targeted NGS sequencing data in an oncological care setting. 2020 , 13, 17	2
885	A Pilot Study of Circulating Monocyte Subsets in Patients Treated with Stem Cell Transplantation for High-Risk Hematological Malignancies. 2020 , 56,	4
884	Updates on DNA methylation modifiers in acute myeloid leukemia. 2020 , 99, 693-701	10
883	Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design. 2020 , 15, e0227986	15
882	Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition. 2020 , 69, 629-640	4
881	Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients. 2020 , 26, 1200-1212	3
880	Clinical value of event-free survival in acute myeloid leukemia. 2020 , 4, 1690-1699	3
879	The sensitivity of the -ITD detection method is an important consideration when diagnosing acute myeloid leukemia. 2020 , 13, 100198	4
878	Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy. 2020 , 10, 443	1
877	Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. 2020 , 34, 2621-2634	13

876	The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. 2020 , 4, 1094-1101	26
875	Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. 2020 , 50, 1374-1385	3
874	Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia. 2020 , 10, 379	5
873	Co-occurrence of PML-RARA gene fusion, chromosome 8 trisomy, and FLT3 ITD mutation in a young female patient with de novo acute myeloid leukemia and early death: A CARE case report. 2020 , 99, e19730	0
872	Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting. 2020 , 190, 891-900	5
871	Outcome of Relapsed or Refractory -Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study. 2020 , 12,	4
870	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. 2020 , 38, 372-380	7
869	Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2020 , 31, 697-712	75
868	Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. 2020 , 44, 100679	12
867	Outcome of Core Binding Factor Acute Myeloid Leukemia by Receptor Tyrosine Kinase Mutation. 2020 , 20, 459-467	1
866	Acute leukemia in the time of COVID-19. 2020 , 92, 106353	33
865	Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. 2020 , 34, 3161-3172	57
864	Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype. 2020 , 10, 5904	2
863	Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. 2020 , 105, 138-147	5
862	Gene coexpression network analysis revealed biomarkers correlated with blast cells and survival in acute myeloid leukemia. 2020 , 12, 475-484	3
861	Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact. 2020 , 15, e0229593	2
860	Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. 2020 , 4, 1670-1677	8
859	The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. 2020 , 21,	55

858	Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation. 2020 , 99, 1845-1853		4
857	Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience. 2020 , 67, e28305		5
856	Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. 2020 , 4, 1615-1623		16
855	Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. 2020 , 105, 2659-2663		36
854	Emerging pharmacotherapies for elderly acute myeloid leukemia patients. 2020 , 13, 619-643		3
853	Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia. 2020 , 21, 34		2
852	Aberrant TRPM4 expression in MLL-rearranged acute myeloid leukemia and its blockade induces cell cycle arrest via AKT/GLI1/Cyclin D1 pathway. 2020 , 72, 109643		3
851	FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 1472-1483	2.2	22
850	Ex-vivo drug testing predicts chemosensitivity in acute myeloid leukemia. 2020 , 107, 859-870		5
849	Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia. 2020 , 38, 425-431		4
848	Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study. 2020 , 92, 106352		
847	The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study. 2020 , 190, 236-243		6
846	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. 2020 , 143, 567-573		24
845	Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 542-546	2.2	28
844	Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. <i>Blood</i> , 2020 , 135, 449-452	2.2	20
843	EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes. 2020 , 25, e1414-e1420		18
842	How I treat acute myeloid leukemia in the era of new drugs. <i>Blood</i> , 2020 , 135, 85-96	2.2	104
841	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 371-380	2.2	53

840	Molecular MRD status and outcome after transplantation in NPM1-mutated AML. <i>Blood</i> , 2020 , 135, 680-688	58
839	Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. <i>Blood</i> , 2020 , 135, 791-803	2.2 176
838	Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. 2020 , 4, 301-311	6
837	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. 2020 , 4, 696-705	21
836	Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia. 2020 , 4, 296-300	10
835	Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. 2020 , 4, 274-286	18
834	Single-cell mutational profiling enhances the clinical evaluation of AML MRD. 2020 , 4, 943-952	28
833	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. 2020 , 4, 1311-1320	57
832	Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia. 2020 , 4, 1206-1216	4
831	Clinical implications of recurrent gene mutations in acute myeloid leukemia. 2020 , 9, 4	24
830	The Changing Landscape of Treatment in Acute Myeloid Leukemia. 2020 , 40, 1-12	5
829	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. 2020 , 105, 1507-1516	34
828	Bibliometric analysis of studies about acute myeloid leukemia conducted globally from 1999 to 2018. 2020 , 55, 1-9	3
827	Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing. 2021 , 35, 47-61	22
826	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. 2021 , 35, 62-74	34
825	The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis. 2021 , 11,	2
824	Mouse Models of Myeloid Malignancies. 2021 , 11,	1
823	Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. 2021 , 144, 66-73	2

822	Repurposing of artemisinin-type drugs for the treatment of acute leukemia. 2021 , 68, 291-312		4
821	Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. 2021 , 106, 894-898		24
820	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. 2021 , 56, 532-535		21
819	Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia. 2021 , 192, 494-503		3
818	Very late acute myeloid leukemia relapse: clinical features, treatment and outcome. 2021 , 62, 1022-1025		1
817	Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome. 2021 , 192, 729-736		5
816	Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. 2021 , 35, 712-723		4
815	Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies. 2021 , 62, 8-31		1
814	How I diagnose and treat NPM1-mutated AML. <i>Blood</i> , 2021 , 137, 589-599	2.2	13
813	Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways. 2021 , 42, 604-612		5
812	Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. 2021 , 35, 225-228		5
811	Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up. 2021 , 100, 595-599		2
810	Outcomes and health care utilization of older patients with acute myeloid leukemia. 2021 , 12, 243-249		1
809	Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). 2021 , 35, 1145-1155		11
808	Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations. 2021 , 35, 1188-1192		2
807	Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission. 2021 , 56, 232-242		
806	Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT. 2021 , 56, 334-346		5
805	Identifying a novel 5-gene signature predicting clinical outcomes in acute myeloid leukemia. 2021 , 23, 648-656		4

804	Potential targeting of FLT3 acute myeloid leukemia. 2021 , 106, 671-681		11
803	Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences. 2021 , 46, 100735		4
802	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. 2021 , 56, 218-224		10
801	Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. 2021 , 56, 101-109		7
800	The role of NF- κ B and Smac/DIABLO proteins in the treatment response and survival of acute myeloid leukemia patients. 2021 , 17, 700-707		0
799	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. 2021 , 27, 68-74		4
798	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. 2021 , 56, 622-634		2
797	Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. 2021 , 27, 153-162		5
796	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. 2021 , 62, 224-228		4
795	Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies. 2021 , 106, 105-113		5
794	Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia. 2021 , 27, 60-69		6
793	Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow. <i>Blood</i> , 2021 , 137, 569-572	2.2	9
792	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. 2021 , 127, 609-618		4
791	Evolving treatment patterns and outcomes in older patients (\geq 60 years) with AML: changing everything to change nothing?. 2021 , 35, 1571-1585		7
790	FLT3 ligand in acute myeloid leukemia: a simple test with deep implications. 2021 , 62, 264-270		2
789	CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. <i>Blood</i> , 2021 , 137, 1037-1049	2.2	15
788	RUNX1 germline variants in RUNX1-mutant AML: how frequent?. <i>Blood</i> , 2021 , 137, 1428-1431	2.2	5
787	WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience. 2021 , 21, e145-e151		2

786	How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). 2021 , 193, 231-244	9
785	Acute Leukemias. 2021 ,	2
784	Budgeting at the Ca store: a PIPeline to starve LSCs?. 2021 , 93, 102309	
783	Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation. 2021 , 27, 639-641	3
782	Alpha-lipoic acid ameliorates cytarabine-induced developmental anomalies in rat fetus. 2021 , 40, 851-868	0
781	Development and performance of a next generation sequencing (NGS) assay for monitoring of mixed chimerism. 2021 , 512, 40-48	3
780	Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML. 2021 , 106, 606-615	1
779	[Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis]. 2021 , 42, 814-822	
778	[Chinese consensus on minimal residual disease detection and interpretation of patients with acute myeloid leukemia (2021)]. 2021 , 42, 889-897	0
777	[Impact of blood count recovery before haploidentical stem cell transplantation on outcomes in acute myeloid leukemia].. 2021 , 42, 1030-1034	
776	TANK-binding kinase 1 inhibitor GSK8612 enhances daunorubicin sensitivity in acute myeloid leukemia cells via the AKT-CDK2 pathway.. 2021 , 13, 13640-13653	
775	Identification of a prognostic signature based on copy number variations (CNVs) and CNV-modulated gene expression in acute myeloid leukemia.. 2021 , 13, 13683-13696	
774	TP53-mutated Acute Myeloid Leukemia and Myelodysplastic Syndrome With Excess Blasts: Two Sides of the Same Coin?. 2022 , 19,	
773	Diagnostic Applications of Nuclear Medicine: Leukemias. 2022 , 1-39	
772	Efficacy and Safety of Midostaurin Combined with Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation. 2022 , 15, 167-175	
771	Acute myeloid leukemia patients with variant or unusual translocations involving chromosomes 8 and 21 [A comprehensive cytogenetic profiling of three cases with review of literature. 2022 ,	
770	Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia.. 2022 , 13, 20406207221093964	0
769	Midostaurin plus intensive chemotherapy for younger and older Patients with AML and FLT3 internal tandem duplications.. 2022 ,	0

768 Standards der kurativen Systemtherapie der akuten myeloischen Leukämie.

767 Pathogenese und molekulare Diagnostik der akuten myeloischen Leukämie. 1

766 A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.. **2022**, 1

1

765 Detection of residual and chemoresistant leukemic cells in an immune-competent mouse model of acute myeloid leukemia: Potential for unravelling their interactions with immunity.. **2022**, 17, e0267508

764 Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.. **2022**, 23,

o

763 Genetic Characteristics According to Subgroup of Acute Myeloid Leukemia with Myelodysplasia-Related Changes.. **2022**, 11,

o

762 The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA.. **2022**, 6, e0708

761 Prognostic impact of PRDM16 expression in acute myeloid leukemia with normal cytogenetics.. **2022**, 27, 499-505

760 Dysregulated Expression of MiR-19b, MiR-25, MiR-17, WT1, and CEBPA in Patients with Acute Myeloid Leukemia and Association with Graft versus Host Disease after Hematopoietic Stem Cell Transplantation.

759 Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.. **2022**, 10, 490

o

758 Novel Prognostic Signature for Acute Myeloid Leukemia: Bioinformatics Analysis of Combined CNV-Driven and Ferroptosis-Related Genes.. **2022**, 13, 849437

2

757 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs.. **2022**, 57, 32-36

1

756 Development of [At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies.. **2022**,

o

755 A Case of Isolated Myeloid Sarcoma Associated With Germline T790M Variant: The Importance of Recognizing Potential Germline Variants on Somatic Tumor Sequencing Panels.. **2022**, 11, 71-76

754 NPM1 exon 5 mutations in acute myeloid leukemia: Implications in diagnosis and minimal residual monitoring.

753 Human acute myeloid leukemia stem cells: evolution of concept.. **2022**, 57, 67-74

1

752 Transcriptome-Wide Analysis of RNA N-Methyladenosine Modification in Adriamycin-Resistant Acute Myeloid Leukemia Cells.. **2022**, 13, 833694

751 A Six-Gene Risk Model Based on the Immune Score Reveals Prognosis in Intermediate-Risk Acute Myeloid Leukemia.. **2022**, 2022, 4010786

o

750	Description and optimization of a multiplex bead-based flow cytometry method (MBFCM) to characterize extracellular vesicles in serum samples from patients with hematological malignancies.. 2022 ,	2
749	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.. 2022 , 9, e350-e360	2
748	Target Therapy for Extramedullary Relapse of -ITD Acute Myeloid Leukemia: Emerging Data from the Field.. 2022 , 14,	0
747	The dual role of autophagy in acute myeloid leukemia.. 2022 , 15, 51	1
746	Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms. 2022 , 118, 106858	
745	Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms.. 2022 ,	1
744	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.. 2022 , 15, 60	2
743	Allogene Stammzelltransplantation bei akuten Leukämien. 1	
742	A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.. 2022 , 1-9	
741	Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.. 2022 ,	0
740	Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.. 2022 ,	0
739	Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.. 2022 , 14,	0
738	FLT3-targeted treatment for acute myeloid leukemia.. 2022 ,	0
737	Venetoclax and acute myeloid leukaemia: an expanding new frontier.. 2022 ,	
736	Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.. 2022 ,	3
735	RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia.. 2022 ,	
734	Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia.. 2022 , 1-6	
733	COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA).. 2022 ,	0

732	Therapeutic Role of Carotenoids in Blood Cancer: Mechanistic Insights and Therapeutic Potential.. 2022 , 14,	1
731	Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy. 11, 495	
730	Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia.. 2022 ,	0
729	Reduced expression of lncRNA DLEU7-AS1 is a novel favorable prognostic factor in acute myeloid leukemia.. 2022 , 42,	0
728	Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review.. 2022 ,	1
727	M2-polarized macrophages control LSC fate by enhancing stemness, homing, immune evasion and metabolic reprogramming.	0
726	Comprehensive analysis of a pyroptosis-related gene signature of clinical and biological value in acute myeloid leukaemia.. 2022 , 108, 108802	0
725	Establishment of tumor protein p53 mutation-based prognostic signatures for acute myeloid leukemia.. 2022 , 70, 103347	
724	Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.. 2022 ,	
723	Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?. 2022 , 14, 2434	1
722	Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges.. 2022 , 1	1
721	Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents: A Prospective Cohort Study of the AGMT Study-Group. 2022 , 14, 2459	2
720	Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure. 2022 , 23, 5555	0
719	Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies.. 2022 ,	0
718	Multomics Analysis Identifies SOCS1 as Restraining T Cell Activation and Preventing Graft-Versus-Host Disease.. 2022 , e2200978	0
717	Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia.. 2022 ,	3
716	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.. 2022 ,	8
715	Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study.. 2022 , 1-11	0

- 714 FLT3 Inhibitors for Acute Myeloid Leukemia: Successes, Defeats, and Emerging Paradigms. 0
- 713 The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia.
- 712 Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial. 0
- 711 Diphenyleneiodonium Triggers Cell Death of Acute Myeloid Leukemia Cells by Blocking the Mitochondrial Respiratory Chain, and Synergizes with Cytarabine. **2022**, 14, 2485 1
- 710 Impact of the MRD status in AML patients undergoing allogeneic stem cell transplantation in first vs second remission. 0
- 709 Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors. **2022**, 23, 5950 1
- 708 Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool. **2022**, 12, 1305 0
- 707 Emerging antibody-based therapies for the treatment of acute myeloid leukemia. **2022**, 108, 102409 0
- 706 Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. **2022**, 1-16 1
- 705 High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. **2022**, 8, 583
- 704 Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. 0
- 703 South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook. **2022**, 11,
- 702 Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia.
- 701 AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome. **2022**, 27, 636-641
- 700 Case Report: Extramedullary Acute Promyelocytic Leukemia: An Unusual Case and Mini-Review of the Literature. 12,
- 699 Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies. **2022**, 22, 1
- 698 A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan + clofarabine in allogeneic stem cell transplantation.
- 697 Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations.

- 696 Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population-based study. ○
- 695 Oncology stewardship in acute myeloid leukemia.
- 694 Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes. **2022**, ○
- 693 An Automated Pipeline for Differential Cell Counts on Whole-Slide Bone Marrow Aspirate Smears. ○
- 692 Efficacy of conventional-dose cytarabine, idarubicin and thioguanine (IAT) versus intermediate-dose cytarabine and idarubicin (IdAraC-Ida) in the induction treatment of AML: long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.
- 691 Serum Metabolomics Coupling With Clinical Laboratory Indicators Reveal Taxonomic Features of Leukemia. **2022**, 13,
- 690 The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing. 1-9
- 689 Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment. ○
- 688 Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment. ○
- 687 New Therapeutic Strategies for Adult Acute Myeloid Leukemia. **2022**, 14, 2806 ○
- 686 Molecular Mechanisms and Therapies of Myeloid Leukaemia. **2022**, 23, 6251
- 685 Application of precision medicine in clinical routine in haematology Challenges and opportunities. 1
- 684 CPX-351 yields similar response and survival outcome in younger and older patients with secondary acute myeloid leukemia. **2022**, ○
- 683 Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience. **2022**, 118, 106861
- 682 Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors. **2022**, 13, 204062072210908
- 681 AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax. **2022**, 17, 100333
- 680 Unbiased decision-making for acute myeloid leukemia still needed. ○
- 679 Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia. **2022**, 14, 2817

678	Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms. 2022 , 14, 2934		
677	Resistance to targeted therapies: delving into FLT3 and IDH. 2022 , 12,		1
676	Effective NPM1 plasmid standards selection for minimal/measurable residual disease monitoring in acute myeloid leukemia.		
675	Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?. 2022 , 14, 2994		2
674	The impact of remission duration on the long-term economic burden of acute myeloid leukemia among patients without hematopoietic stem cell transplant in the United States. 1-13		
673	Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.		1
672	Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients \geq 5 years of age.		0
671	Real-world treatment patterns and clinical outcomes in Korean patients with AML ineligible for first-line intensive chemotherapy: A subanalysis of the CURRENT study, a non-interventional, retrospective chart review.		
670	Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence from Thai Acute Myeloid Leukemia Registry. 2022 ,		0
669	High-Risk Acute Myeloid Leukemia: A Pediatric Prospective. 2022 , 10, 1405		
668	Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms. 12,		
667	A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.		0
666	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. <i>Blood</i> ,	2.2	1
665	Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients. 2022 ,		
664	Studying the potential of upregulated PTGS2 and VEGF-C besides hyper-methylation of PTGS2 promoter as biomarkers of Acute myeloid leukemia.		
663	A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed or Refractory AML Harboring RAS Pathway-Activating Mutations.		1
662	Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes.		2
661	Expression and prognostic significance of chromatin modulators EHMT2/G9a and KDM2b in acute myeloid leukemia.		1

660	Somatic mutation-associated risk index based on lncRNA expression for predicting prognosis in acute myeloid leukemia. 2022 , 27, 659-671	0
659	How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia.	1
658	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.	1
657	Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study. 2022 , 11, 916	2
656	Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas. 2022 , 14, 3037	1
655	Re-induction versus Salvage for D14-residual Acute Myeloid Leukemia: A Retrospective multi-center Study. 2022 , 106902	1
654	A multiparametric niche-like drug screening platform in acute myeloid leukemia. 2022 , 12,	0
653	Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myeloid Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. 2022 ,	
652	Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.	0
651	Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic. 1-4	
650	Leukemia derived dendritic cell (DCleu) mediated immune response goes along with reduced (leukemia-specific) regulatory T-cells. 2022 , 227, 152237	0
649	Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax. 2022 , 119, 106904	0
648	Hematopoietic stem cell transplantation: Sources of cells, cryopreservation, and applications. 2022 , 229-255	
647	Oncohematology. 2022 , 365-407	
646	Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant. 2022 , 158, 451-457	
645	A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells. 28,	1
644	Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.	
643	Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group. 2022 , 10, 1530	0

- 642 Screening a Targeted Panel of Genes by Next-Generation Sequencing Improves Risk Stratification in Real World Patients with Acute Myeloid Leukemia. **2022**, 14, 3236
- 641 Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia. **2022**, 10, 33 ○
- 640 Acute Myeloid Leukaemia Drives Metabolic Changes in the Bone Marrow Niche. 12, ○
- 639 Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification. **2022**, 14, 3199 1
- 638 Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis. OF1-OF9 ○
- 637 Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r.
- 636 Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia. ○
- 635 Molecular Profiling of Kenyan Acute Myeloid Leukemia Patients. 13,
- 634 Vitamin C Deficiency in Patients With Acute Myeloid Leukemia. 12,
- 633 Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. 1
- 632 Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.
- 631 Clinical features of hepatitis E infections in patients with hematological disorders. ○
- 630 Myelodysplastic Syndrome: Diagnosis and Screening. **2022**, 12, 1581
- 629 Molecular Characterization of a First-in-Human Clinical Response to Nimesulide in Acute Myeloid Leukemia. 12,
- 628 Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios. **2022**, 13, ○
- 627 DNA methyltransferase-1 in acute myeloid leukaemia: beyond the maintenance of DNA methylation. **2022**, 54, 2011-2023 1
- 626 Controlled variable selection in Weibull mixture cure models for high-dimensional data. ○
- 625 Immune landscape after allo-HSCT: TIGIT and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse. *Blood*, 2.2 1

- 624 Beyond Pathogenic RUNX1 Germline Variants: The Spectrum of Somatic Alterations in RUNX1-Familial Platelet Disorder with Predisposition to Hematologic Malignancies. **2022**, 14, 3431 0
- 623 Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells. 12, 0
- 622 Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. 0
- 621 Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. **2022**, 14, 3456 3
- 620 New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes. **2022**, 23, 7542 0
- 619 21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature review. **2022**, 15, 0
- 618 Molecular dissection of a hyper-aggressive CBFβ-MYH11/FLT3-ITD^β positive acute myeloid leukemia. **2022**, 20, 0
- 617 Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine. 1-7 0
- 616 Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/ KMT2A rearrangements. 0
- 615 HMGA2 expression defines a subset of AML with immature transcriptional signature and vulnerability to G2/M inhibition. 0
- 614 Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody. 1
- 613 Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. 0
- 612 High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. 0
- 611 Droplet digital PCR for genetic mutations monitoring predicts relapse risk in pediatric acute myeloid leukemia. 0
- 610 Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays. **2022**, 13, 1
- 609 A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. **2022**, 12, 1
- 608 Deregulation of CircANXA2, Circ0075001, and CircFBXW7 Gene Expressions and Their Predictive Value in Egyptian Acute Myeloid Leukemia Patients. Volume 15, 69-85 0
- 607 Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer. **2022**, 194, 507-516 0

606	Flipping the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors. 2022 , 14, 3398		2
605	Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. 2022 , 10, e004222		0
604	Understanding ER homeostasis and the UPR to enhance treatment efficacy of Acute Myeloid Leukemia. 2022 , 100853		0
603	Revealing the dark secrets of TP53-mutated AML. <i>Blood</i> , 2022 , 140, 8-10	2.2	0
602	5-Demethylnobiletin Inhibits Cell Proliferation, Downregulates ID1 Expression, Modulates the NF- κ B/TNF- α Pathway and Exerts Antileukemic Effects in AML Cells. 2022 , 23, 7392		0
601	Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation. 2022 , 14, 3307		
600	Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism. 2022 , 2022, 1-12		0
599	Association of FLT3-ITD length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis.		0
598	Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. 2022 , 6, 4098-4106		1
597	Improved outcomes with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data.		
596	Acute Myeloid Leukemia: New Multiomics Molecular Signatures and Implications for Systems Medicine Diagnostics and Therapeutics Innovation. 2022 , 26, 392-403		0
595	Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. 2022 , 100991		1
594	Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia.		
593	Low IL7R Expression at Diagnosis Predicted Relapse in Adult Acute Myeloid Leukemia Patients With t(8;21). 13,		
592	Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. <i>Blood</i> ,	2.2	60
591	Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy. 11, 495		
590	A novel heptasomy 21 associated with complete loss of heterozygosity and loss of function RUNX1 mutation in acute myeloid leukemia. 2022 , 266-267, 69-73		
589	Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with RUNX1::RUNX1T1. 2022 , 42, 678-682		1

- 588 Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia. Publish Ahead of Print,
- 587 Plasmacytoid Dendritic Cells, a Novel Target in Myeloid Neoplasms. **2022**, 14, 3545 0
- 586 Double-stranded RNA induction as a potential dynamic biomarker for DNA-demethylating agents. **2022**,
- 585 Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. **2022**, 4
- 584 Large-scale in vitro and in vivo CRISPR-Cas9 knockout screens identify a 16-gene fitness score for improved risk assessment in acute myeloid leukemia.
- 583 High-Throughput CRISPR Screening in Hematological Neoplasms. **2022**, 14, 3612 0
- 582 Erstlinientherapie intensiv-therapierbarer AML-Patient*innen. **2022**, 25, 16-21
- 581 Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience. 1-8
- 580 Comprehensive Analysis of CRIP1 Expression in Acute Myeloid Leukemia. 13,
- 579 Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. 1
- 578 Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia. **2022**, 12, 0
- 577 Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT. 0
- 576 Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience. **2022**, 10, 0
- 575 Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML. 0
- 574 Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road.
- 573 Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia. **2022**, 14, 3634 1
- 572 Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens. 0
- 571 Combining empirical knowledge, in silico molecular docking and ADMET profiling to identify therapeutic phytochemicals from *Brucea antidysentrica* for acute myeloid leukemia. **2022**, 17, e0270050 3

- 570 Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1. *Blood*, 2.2 3
- 569 Precision Medicine in Therapy of Non-solid Cancer. **2022**,
- 568 Cell Selection-based Data Reduction Pipeline for Whole Slide Image Analysis of Acute Myeloid Leukemia. **2022**,
- 567 De novo acute myeloid leukemia harboring concomitant t(8;21)(q22;q22);RUNX1::RUNX1T1 and BCR::ABL1 (p190 minor transcript).
- 566 Generation of Leukaemia-Derived Dendritic Cells (DCleu) to Improve Anti-Leukaemic Activity in AML: Selection of the Most Efficient Response Modifier Combinations. **2022**, 23, 8333 0
- 565 Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine. **2022**, 14, 3576 0
- 564 The mythological chimera and new era of relapse prediction post-transplant. **2022**, 100997 0
- 563 Prognostic value and potential mechanism of long non-coding RNA Lnc-SMIM20-1 in acute myeloid leukemia. **2022**, 22, 875-885 0
- 562 Development and validation of a prognostic scoring model to risk stratify childhood acute myeloid leukaemia. 1
- 561 Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia. 12,
- 560 Ferroptosis-related gene signature predicts the clinical outcome in pediatric acute myeloid leukemia patients and refines the 2017 ELN classification system. 9, 1
- 559 A bavachinin analog, D36, induces cell death by targeting both autophagy and apoptosis pathway in acute myeloid leukemia cells. **2022**, 90, 251-265
- 558 NPM1-Mutated Patient-Derived AML Cells Are More Vulnerable to Rac1 Inhibition. **2022**, 10, 1881 1
- 557 Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia.
- 556 Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: Real World Data From Germany. **2022**, 6, e759
- 555 Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives. **2022**, 100996 0
- 554 Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia – Grand Ouest Against Leukemia (GOAL) study.
- 553 The effect of haploidentical hematopoietic stem cell transplantation on computations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation.

552	The hedgehog pathway in hematopoiesis and hematological malignancy. 12,	1
551	Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.	1
550	Unified classification and risk-stratification in Acute Myeloid Leukemia. 2022, 13,	4
549	Clinical manifestations of clonal hematopoiesis: what has SF3B1-mutant MDS taught us?. 2022,	0
548	Single cell genomics in AML: extending the frontiers of AML research.	1
547	Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia. 10,	1
546	Disparities in mortality among acute myeloid leukemia-related hospitalizations.	
545	The signature based on seven genomic instability-related genes could predict the prognosis of acute myeloid leukemia patients. 2022, 27, 840-848	1
544	Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies.	
543	Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia. 2022, 22,	1
542	Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.	0
541	m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia. 13,	
540	Targeting FHL1 impairs cell proliferation and differentiation of acute myeloid leukemia cells.	
539	Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US.	1
538	Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy.	4
537	Discontinuation of azacitidine in acute myeloid leukemia: a feasible option?.	0
536	CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia towards V α + T cell cytotoxicity.	0
535	Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis. 12,	0

534	Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.	0
533	Wilms tumor 1 gene expression in acute myeloid leukemia: prognostic significance and usefulness in minimal residual disease monitoring: a case-control study. 2022 , 23,	
532	Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.	3
531	Integration of CD34+CD117dim population signature improves the prognosis prediction of acute myeloid leukemia. 2022 , 20,	
530	Lipids and the cancer stemness regulatory system in acute myeloid leukemia.	1
529	Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.	0
528	Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance. 2022 , 40, 111177	2
527	FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia. 2022 , 14, 4006	1
526	Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein.	
525	Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome. 2022 , 1033360	0
524	Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia.	
523	Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial.	0
522	Nucleotide depletion promotes cell fate transitions by inducing DNA replication stress.	0
521	Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes. 1-10	
520	No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group. 2022 , 2022, 1-9	
519	Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine.	3
518	Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. 2022 , 36, 2218-2227	0
517	Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia.	0

516	Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia.	0
515	Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia. 2022 , 12,	1
514	Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: A Study from the Acute Leukemia Working Party of the EBMT.	
513	High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. 2022 , 36, 2306-2316	5
512	Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications.	1
511	Presence of the GF11-36N single nucleotide polymorphism enhances the response of MLL-AF9 leukemic cells to CDK4/6 inhibition. 12,	
510	Correlation Analysis and Prognostic Impacts of Biological Characteristics in Elderly Patients with Acute Myeloid Leukemia. Volume 17, 1187-1197	1
509	Chasing leukemia differentiation through induction therapy, relapse and transplantation. 2022 , 101000	
508	Germline predisposition variants occur in myelodysplastic syndrome patients of all ages.	1
507	Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemiaFrom bench to bedside. 10,	1
506	Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia. 2022 , 242, 109083	0
505	Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia. 2022 , 153, 113527	0
504	Acquired somatic variants confirm the independent development of AML in monozygotic twins with germline CEBPA variant. 2022 , 121, 106933	
503	Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults.	0
502	Evaluation of two new highly multiplexed PCR assays as an alternative to next-generation sequencing for IDH1 /2 mutation detection.	0
501	Genome-Based Medicine for Acute Myeloid Leukemia: Study and Targeting of Molecular Alterations and Use of Minimal Residual Disease as a Biomarker. 2022 , 3, 543-568	0
500	Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients. 2022 , 12,	2
499	Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. 1-9	2

498	FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches.	0
497	Developments and challenges of FLT3 inhibitors in acute myeloid leukemia. 12,	1
496	EXABS-100-AML Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?. 2022 , 22, S3-S5	0
495	EXABS-150-AML Is MRD More Prognostic than Initial Presentation Characteristics in AML Patients?. 2022 , 22, S59-S60	0
494	Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia. 2022 , 122, 106946	0
493	Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. 2022 , 122, 106942	0
492	Molecular evaluation of gene mutation profiles and copy number variations in pediatric acute myeloid leukemia. 2022 , 122, 106954	0
491	Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation. 2022 , 13, 204062072211150	0
490	Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD. 2022 , 13, 204062072211275	0
489	MicroRNA in leukemia. 2022 , 429-468	0
488	Cytogenetic Characterization of Complex Karyotypes by Multicolor FISH in Myelodysplastic Syndromes and Associated Acute Myeloid Leukemias. 2022 , 15, 396-413	0
487	Genetic basis of acute myeloid leukemia (AML): The most common molecular changes in patients with normal karyotype. 2022 , 76, 339-344	0
486	Diagnostic Applications of Nuclear Medicine: Leukemias. 2022 , 529-567	0
485	Plasminogen Activator Inhibitor-1 in Acute Myeloid Leukemia: Is It Useful in Predicting Response to Induction Remission Therapy?. 2022 , 10, 1894-1898	0
484	FLT3?????????????????????. 2022 ,	0
483	Risk stratification by 30-day prognostic factors of clinical outcomes after granulocyte transfusion in acute myeloid leukemia: A single-center retrospective study. 2022 , 17, e0273827	0
482	Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.	0
481	Clinically relevant variation in FLT3-ITD quantitation as a result of PCR cycle number and ITD insertion size. 2022 ,	1

- 480 Genetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells. **2022**, 14, 4132 ○
- 479 Know when to fold \bar{m} : Polycomb complexes in oncogenic 3D genome regulation. 10, ○
- 478 Accelerated and blast phase myeloproliferative neoplasms. **2022**, 101379 1
- 477 Haplo-Peripheral Blood Stem Cell Plus Cord Blood Grafts for Hematologic Malignancies Might Lead to Lower Relapse Compared with Haplo-Peripheral Blood Stem Cell Plus Bone Marrow Grafts. **2022**, ○
- 476 Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients. 12, ○
- 475 A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges. **2022**, 14, 4166 ○
- 474 Clinical Application of Biomarkers for Hematologic Malignancies. **2022**, 150-212 ○
- 473 Impact of Cytogenetic Risk on Outcomes of Non-T-Cell Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia. **2022**, ○
- 472 Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML. **2022**, 2
- 471 Case report: A *Saprochaete clavata* (*Magnusiomyces clavatus*) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma. 12, ○
- 470 Identification of the Thyrotropin-Releasing Hormone (TRH) as a Novel Biomarker in the Prognosis for Acute Myeloid Leukemia. **2022**, 12, 1359 ○
- 469 Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. ○
- 468 Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulphan Conditioning: A Retrospective Monocentric Study. **2022**, 1
- 467 Machine Learning Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine. **2022**, ○
- 466 Allogeneic hematopoietic cell transplantation for patients with relapsed acute promyelocytic leukemia. **2022**, 1
- 465 Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-Up A Single Center Experience. **2022**, 14, 4716 ○
- 464 RNA cytometry of single-cells using semi-permeable microcapsules. ○
- 463 Flow Cytometric Identification of Hematopoietic and Leukemic Blast Cells for Tailored Clinical Follow-Up of Acute Myeloid Leukemia. **2022**, 23, 10529 ○

- 462 Network pharmacology-based investigation and experimental validation of the mechanism of scutellarin in the treatment of acute myeloid leukemia. 13, 0
- 461 Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection. **2022**, 14, 4504 0
- 460 The research progress of targeted therapy in acute myeloid leukemia based on bibliometric analysis. 12, 0
- 459 How thinly can one slice the AML diagnostic pie?. **2022**, 140, 1330-1331 1
- 458 Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia. 5
- 457 Triple targeted therapy is a new perspective treatment strategy for patients with FLT3-mutated acute myeloid leukemia. the literature review and single-centre experience. **2022**, 2, 63-76 0
- 456 Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study. 0
- 455 Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. 1-12 0
- 454 The role of next-generation sequencing in acute myeloid leukemia. Publish Ahead of Print, 1
- 453 Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment. **2022**, 14, 0
- 452 Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients. 1-4 0
- 451 Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?. 12, 0
- 450 The Identification of APOBEC3G as a Potential Prognostic Biomarker in Acute Myeloid Leukemia and a Possible Drug Target for Crotonoside. **2022**, 27, 5804 0
- 449 How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes. **2022**, 14, 4519 2
- 448 Molecular Diagnostic Testing for Hematopoietic Neoplasms. **2022**, 42, 325-347 0
- 447 Adult-onset hereditary myeloid malignancy and allogeneic stem cell transplantation. 12, 0
- 446 Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999. **2022**, 12, 0
- 445 Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation. **2022**, 15, 0

444	Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). 1-5	0
443	Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.	0
442	Loss of NPM2 Expression Is A Potential Immunohistochemical Marker for Malignant Peritoneal Mesothelioma : A Single-Center Study of 92 Cases.	0
441	Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy. 2022 , 29, 6794-6806	0
440	Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.	0
439	Clinical implications and genetical insights of SOX6 expression in acute myeloid leukemia.	0
438	Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia Across Therapy Subtypes.	1
437	A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML. 1-4	0
436	Signatures of immune dysfunction predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.	2
435	Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.	0
434	Relationship Between Pre-Transplant Nutritional Status and Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. 2022 ,	0
433	Pulmonary Function is a Strong Predictor of 2-year Overall Survival and Non-relapse Mortality after Allogenic Hematopoietic Cell Transplantation.	0
432	Enasidenib as Maintenance following Allogeneic Hematopoietic Cell Transplantation for IDH2-Mutated Myeloid Malignancies.	1
431	Exposure-Response Relationship of Posaconazole Suspension in Theprophylaxis of Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.	0
430	Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis.	0
429	Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia.	1
428	Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial. 2022 , 12,	0
427	Hijacking Host Immunity by the Human T-Cell Leukemia Virus Type-1: Implications for Therapeutic and Preventive Vaccines. 2022 , 14, 2084	0

426	Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML. 1-7	0
425	Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis. 1-2	0
424	Healthy-like CD4+ Regulatory and CD4+ Conventional T-Cell Receptor Repertoires Predict Protection from GVHD Following Donor Lymphocyte Infusion. 2022 , 23, 10914	0
423	Comprehensive analysis of ECHDC3 as a potential biomarker and therapeutic target for acute myeloid leukemia: Bioinformatic analysis and experimental verification. 12,	0
422	Auer rods and faggot cells: A review of the history, significance and mimics of two morphological curiosities of enduring relevance.	0
421	Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia. 2022 , 10, e005400	1
420	Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia. 2022 , 12, 1607	0
419	Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival.	0
418	Allogeneic haematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukaemia: A single-centre experience. 2022 ,	0
417	PHF6 mutation is associated with poor outcome in acute myeloid leukaemia.	0
416	High-dimensional genomic feature selection with the ordered stereotype logit model.	0
415	CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations. 2022 , 12,	2
414	CALR loss-of-heterozygosity as a potential driver for extramedullary AML. 2022 , 101, 2571-2573	0
413	Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia. 2022 , 12,	0
412	BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes. 2022 , 23, 1-15	0
411	Updates on the Management of Acute Myeloid Leukemia. 2022 , 14, 4756	0
410	FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation. Volume 12, 137-147	1
409	The Down-Regulation of Circ_0059707 in Acute Myeloid Leukemia Promotes Cell Growth and Inhibits Apoptosis by Regulating miR-1287-5p. 2022 , 29, 6688-6699	0

408	Broad genomic workup including optical genome mapping uncovers a DDX3X: MLLT10 gene fusion in acute myeloid leukemia. 12,	1
407	MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?. 2022, 14, 4294	0
406	Cytogenetic profile of adult acute myeloid leukemia in Egypt: a single-center experience. 2022, 15,	0
405	Five EMT-Related Gene Signatures Predict Acute Myeloid Leukemia Patient Outcome. 2022, 2022, 1-8	0
404	Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse. 13,	0
403	Association of FLT3-ITD length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis.	0
402	A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older.	1
401	Therapy related myeloid neoplasms following PARP inhibitors: real-life experience.	0
400	Treatment options for acute myeloid leukemia patients aged <60 years. 12,	0
399	Pathogenic Mechanisms in Acute Myeloid Leukemia.	0
398	Significance of bone marrow fibrosis in acute myeloid leukemia for survival in the real-world. 12,	0
397	Ligand-based discovery of a novel GATA2 inhibitor targeting acute myeloid leukemia cells. 2,	0
396	Circulating plasma exosomal long non-coding RNAs LINC00265, LINC00467, UCA1, and SNHG1 as biomarkers for diagnosis and treatment monitoring of acute myeloid leukemia. 12,	0
395	Contemporary evaluation of acute myeloid leukemia patients with long-term survival exceeding 5 years.	0
394	3. Current Status and Issues in Genomic Medicine in the Area of Blood Cancers. 2021, 110, 1890-1897	0
393	Reprogramming Carbohydrate Metabolism in Cancer and Its Role in Regulating the Tumor Microenvironment. 2022, 3-65	0
392	Current strategies for the treatment of acute myeloid leukemia. 2022, 75, 11-14	0
391	Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study. 2022, 18, 100354	0

390	Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML. 2022 , 10, 2441	2
389	Hematopoietic Cell Transplantation. 1-13	0
388	Chromosomal Aberrations in Cancer. 1-19	0
387	Pre-MEASURE:FLT3-ITD and mutatedNPM1measurable residual disease before allogeneic transplant in adults with AML in first remission.	0
386	Pan-cancer analysis of oncogenic TNFAIP2 identifying its prognostic value and immunological function in acute myeloid leukemia. 2022 , 22,	0
385	Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia. 2022 , 23, 12708	0
384	Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial. 2022 , 15,	0
383	Clinical application of molecular genetics in acute myeloid leukemia. 1-6	0
382	Real world molecular characterisation and clonal evolution of acute myeloid leukaemia reveals therapeutic opportunities and challenges. 2022 ,	0
381	A glimpse into translocation (8;21) in acute myeloid leukemia: Profile and therapeutic outcomes from a tertiary care hematology center from East India. 2, 85-90	0
380	Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications.	0
379	Clinical Validation and Diagnostic Utility of Optical Genome Mapping for Enhanced Cytogenomic Analysis of Hematological Neoplasms. 2022 ,	2
378	A novel use of CT attenuation value: increased bone marrow density in patients with acute myeloid leukemia. 028418512211351	0
377	Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian CostUtility Analysis. 2022 , 29, 7524-7536	0
376	Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.	0
375	Risk Stratification of Acute Myeloid Leukemia Using Ex Vivo Drug Sensitivity Profiling.	0
374	The International Consensus Classification of acute myeloid leukemia.	1
373	Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.	0

- 372 Subtype-specific 3D genome alteration in acute myeloid leukaemia. 1
- 371 Conduite à tenir devant une prédisposition génétique aux hémopathies malignes chez un patient candidat à l'allogreffe de cellules souches hématopoïétiques (CSH) : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). 2022, 0
- 370 An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients. 1
- 369 Identification of the immunosuppressive effect of T_H cells correlated to bone morphogenetic protein 2 in acute myeloid leukemia. 13, 0
- 368 Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. 1
- 367 Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group. 0
- 366 Comprehensive Genomic Profiling Reveals Molecular Subsets of ASXL1-Mutated Myeloid Neoplasms. 0
- 365 RNA cytometry of single-cells using semi-permeable microcapsules. 0
- 364 How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms. 2022, 101405 0
- 363 The new diagnostic criteria for myelodysplasia-related acute myeloid leukemia is useful for predicting clinical outcome: comparison of the 4th and 5th World Health Organization classifications. 0
- 362 Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis. 12, 0
- 361 Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia. 0
- 360 Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis. 2022, 14, 5239 1
- 359 Differential diagnosis of leukocytosis and leukopenia. 2022, 68, E28-E35 0
- 358 A Novel Bead-Capture Nanopore Sequencing Method for Large Structural Rearrangement Detection in Cancer. 2022, 0
- 357 A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. 0
- 356 Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. 1-9 0
- 355 Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review. 1-10 0

354	Mutation of the TP53 gene in acute lymphoblastic leukemia does not affect survival outcomes after haploidentical hematopoietic stem cell transplantation.	0
353	Acute Myeloid Leukemia in Adults: Mast Cell Leukemia and Other Mast Cell Neoplasms. 1-21	0
352	A British Society for Haematology good practice paper: Recommendations for laboratory testing of UK patients with acute myeloid leukaemia.	1
351	Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases. 2022 , 20,	0
350	Diagnostic Approach for Acute Myeloid Leukemia Based on the World Health Organization Classification of Hematologic Neoplasms. 2022 , 97, 308-318	0
349	Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission. 2022 , 22,	0
348	Next-generation sequencing revealed factors associated with cumulative incidence of relapse and leukemia-free survival in patients with newly diagnosed acute myeloid leukemia. 2022 ,	0
347	Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia. 12,	0
346	Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.	0
345	The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia.	0
344	Naturally Selected CD7 CAR-T Therapy without Genetic editing Exerts Significant Antitumor Efficacy against Relapsed and Refractory Acute Myeloid Leukemia(R/R-AML).	0
343	The RNA m6A reader YTHDF1 promotes hematopoietic malignancy by maintaining oncogenic translation.	0
342	Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience. 2022 , 14, 4897	0
341	C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse.	1
340	Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.	0
339	Revisiting Co-existing Chromosomal Abnormalities in NPM1-mutated AML in Light of the Revised ELN 2022 classification.	0
338	Prognostic impact of unsupervised early assessment of bulk and leukemic stem cell measurable residual disease in acute myeloid leukemia.	0
337	How Can We Intervene to Mitigate Post-transplantation Relapse in AML? Strategies to Mitigate Post-transplantation Relapse in AML. 2022 , 101411	0

- 336 Very early death within 30 days after diagnosis in patients with acute myeloid leukemia. ○
- 335 Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients. 1
- 334 A Bioinformatics View on Acute Myeloid Leukemia Surface Molecules by Combined Bayesian and ABC Analysis. **2022**, 9, 642 ○
- 333 TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs. 1-11 1
- 332 Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours. 1-14 ○
- 331 Resistance to targeted therapies in acute myeloid leukemia. ○
- 330 Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia. **2022**, 123, 106970 ○
- 329 Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling. **2022**, 123, 106971 ○
- 328 Evidence-based support for phenotypic drug discovery in acute myeloid leukemia. **2022**, 27, 103407 ○
- 327 Significance of Gene Diagnosis in Acute Myeloid Leukemia with the Emergence of New Molecular Target Drug Treatment. **2022**, 89, 470-478 ○
- 326 Early changes in gene expression profiles in AML patients during induction chemotherapy. **2022**, 23, ○
- 325 Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. **2022**, 23, ○
- 324 Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes. ○
- 323 Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience. **2022**, 14, 5640 ○
- 322 Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis. ○
- 321 Comparison of fragment analysis and PCR electrophoresis methods for the detection of FLT3-ITD mutations in patients with acute myeloid leukemia. **2022**, 17, 118-125 ○
- 320 Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation. **2022**, 12, ○
- 319 The lower relapse rate and better survival advantages of haploidentical allograft compared with HLA-matched sibling donor allografts for intermediate- and adverse-risk AML patients with pretransplantation minimal residual disease. ○

318	The adverse impact of ecotropic viral integration site-1 (EVI1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes.	0
317	Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.	0
316	Individualized busulfan dosing improves outcomes compared to fixed dose administration in pre-transplant MRD positive AML patients with intermediate risk undergoing allogeneic stem cell transplantation in CR.	0
315	Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC -defining criteria, TP53 allelic state, or TP53 variant allele frequency.	0
314	SOHO State of the Art Updates and Next Questions The Role of Maintenance Therapy in Acute Myeloid Leukemia. 2022,	0
313	The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia.	0
312	Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.	0
311	Somatic mutations of activating signalling, transcription factor, and tumour suppressor are a precondition for leukaemia transformation in myelodysplastic syndromes.	0
310	Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.	0
309	Identification of microRNA editing sites in three subtypes of leukemia. 9,	0
308	Cusatuzumab Plus Azacitidine in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Treatment.	0
307	Myelodysplastic syndromes. 2022, 8,	0
306	Outcomes after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with der(1;7)(q10;p10).	0
305	Real-life challenges using personalized prognostic scoring systems in acute myeloid leukemia.	0
304	Referral to and receipt of allogeneic hematopoietic stem cell transplantation in older adults with acute myeloid leukemia. 2022,	0
303	An Immunogenic Cell Death-Based Risk model Predicts Prognosis and Indicates Immune Infiltration Landscape in Acute Myeloid Leukemia.	0
302	Clofarabine and busulfan myeloablative conditioning in allogeneic hematopoietic cell transplant for patients with active myeloid malignancies. 2022,	0
301	BCNet: A Deep Learning Computer-Aided Diagnosis Framework for Human Peripheral Blood Cell Identification. 2022, 12, 2815	4

300	Flavones, Flavonols, Lignans, and Caffeic Acid Derivatives from <i>Dracocephalum moldavica</i> and Their In Vitro Effects on Multiple Myeloma and Acute Myeloid Leukemia. 2022 , 23, 14219	1
299	Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation.	2
298	Nanoparticles as Emerging Diagnostic Tools in Liquid Tumours. 80-87	0
297	Advances and Future Goals in Acute Myeloid Leukaemia Therapy. 2022 , 18, 130	0
296	Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia. 2023 , 124, 107002	0
295	Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. 2023 ,	0
294	Chimeric antigen receptor T-cell therapy for T-ALL and AML. 12,	1
293	Ferroptosis-related molecular patterns reveal immune escape, inflammatory development and lipid metabolism characteristics of the tumor microenvironment in acute myeloid leukemia. 12,	0
292	Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.	2
291	Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia. 2022 , 14, 5906	0
290	The clinical and biological characterization of acute myeloid leukemia patients with S100A4 overexpression. 2022 ,	0
289	Hypomethylating agent-based therapies in older adults with acute myeloid leukemia [A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee. 2022 ,	0
288	Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation. 2022 , 17,	0
287	Comprehensive analysis of ID genes reveals the clinical and prognostic value of ID3 expression in acute myeloid leukemia using bioinformatics identification and experimental validation. 2022 , 22,	0
286	A Novel Prognostic Model for Acute Myeloid Leukemia Based on Gene Set Variation Analysis. 2022 , 2022, 1-13	0
285	CLINICAL FEATURES OF FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA CASES AND THE ROLE OF FLT3 INHIBITORS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA: A SINGLE CENTER EXPERIENCE.	0
284	Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML).	0
283	Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches. Volume 15, 1449-1478	0

- 282 The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients. 12, ○
- 281 Applying molecular measurable residual disease testing in acute myeloid leukaemia. **2022**, ○
- 280 Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value. **2022**, 23, 14885 ○
- 279 High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia. 12, ○
- 278 Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia. ○
- 277 Evaluating the clinical significance of FLT3 mutation status in Syrian newly diagnosed acute myeloid leukemia patients with normal karyotype. **2022**, 8, e11858 ○
- 276 Role of Biomarkers in the Management of Acute Myeloid Leukemia. **2022**, 23, 14543 ○
- 275 Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms. ○
- 274 Patient-centered communication tool for older patients with acute myeloid leukemia, their caregivers, and oncologists: A single-arm pilot study. ○
- 273 Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. **2022**, 12, 2
- 272 Upfront Screening by Quantitative Real-Time PCR Assay Identifies NUP98::NSD1 Fusion Transcript in Indian AML Patients. **2022**, 12, 3001 ○
- 271 Cerebrospinal fluid interleukin-6 is a potential diagnostic biomarker for central nervous system involvement in adult acute myeloid leukemia. 12, ○
- 270 FLT3-ITD Measurable Residual Disease Monitoring in Acute Myeloid Leukemia Using Next-Generation Sequencing. **2022**, 14, 6121 ○
- 269 Achieving MRD negativity in AML: how important is this and how do we get there?. **2022**, 2022, 9-14 ○
- 268 Optimizing outcomes in secondary AML. **2022**, 2022, 23-29 ○
- 267 Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. **2022**, 12, ○
- 266 Establishment and validation of a carbohydrate metabolism-related gene signature for prognostic model and immune response in acute myeloid leukemia. 13, ○
- 265 Allogeneic stem cell transplant improves survival after first- or second-line therapy in TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).. ○

- 264 Clinical outcome and prognosis of patients with acute myeloid leukemia submitted to chemotherapy with 5 years of follow-up. **2022**, ○
- 263 Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts. **2022**, 2022, 218-224 ○
- 262 Is the AURKB Gene Involved in Aml Cell Proliferation Since It is Targeted by miR-34a-5p and let-7b-5p?. ○
- 261 Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children. ○
- 260 The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia. ○
- 259 A transient receptor potential channel-related model based on machine learning for evaluating tumor microenvironment and immunotherapeutic strategies in acute myeloid leukemia. 13, ○
- 258 Single cell guided deconvolution of bulk transcriptomics recapitulates differentiation stages of acute myeloid leukemia and predicts drug response. ○
- 257 Complex Roles of NEIL1 and OGG1: Insights Gained from Murine Knockouts and Human Polymorphic Variants. **2022**, 2, 279-301 ○
- 256 Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively. **2023**, 7, e819 ○
- 255 Real-World Efficacy Outcomes of FLT3-ITD Acute Myeloid Leukemia Patients Treated with Midostaurin in Combination with Intensive Induction. **2022**, ○
- 254 An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. **2022**, ○
- 253 Cytogenetic evolution predicts a poor prognosis in acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation. ○
- 252 Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component. **2022**, 14, 6244 ○
- 251 Impact of insurance status and distance from residence to treatment center on the outcomes of patients diagnosed with acute myeloid leukemia. 1, ○
- 250 Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy. ○
- 249 Biallelic TET2 mutation sensitizes to 5-azacitidine in acute myeloid leukemia. ○
- 248 Acute Myeloid Leukemia Revealed by a Palatal Necrosis: A Rare Case Report. **2022**, ○
- 247 The present and future of measurable residual disease testing in acute myeloid leukemia. **2022**, 107, 2810-2822 ○

- 246 Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3. **2022**, 2022, 15-22 ○
- 245 CD34 negative HLA-DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3-ITD mutations. ○
- 244 Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia. ○
- 243 Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogeneic stem cell transplantation in a patient with 11q23/MLL-rearranged complex karyotype acute myeloid leukemia. ○
- 242 Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML. 12, ○
- 241 A randomized phase II/III study of novel therapeutics versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and venetoclax versus azacitidine. [doi:10.1182/blood-2021-15-411212](#) ○
- 240 Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. ○
- 239 Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia. **2022**, 22, ○
- 238 Construction and validation of a fatty acid metabolism risk signature for predicting prognosis in acute myeloid leukemia. **2022**, 23, ○
- 237 Early-onset venous thromboembolisms in newly diagnosed non-promyelocytic acute myeloid leukemia patients undergoing intensive induction chemotherapy. ○
- 236 First-in-Human Study of JNJ -63709178, a CD123 / CD3 Targeting Antibody, in Relapsed/Refractory Acute Myeloid Leukemia. ○
- 235 Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML). **2022**, 20, ○
- 234 Baseline Acute Myeloid Leukemia Prognosis Models using Transcriptomic and Clinical Profiles by Studying the Impacts of Dimensionality Reductions and Gene Signatures on Cox-Proportional Hazard. ○
- 233 Evidence-Based Minireview: Clinical utilization of panel-based molecular testing for patients with AML. **2022**, 2022, 30-33 ○
- 232 Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes. Volume 14, 3527-3538 ○
- 231 Genetic changes in refractory relapsed acute myeloid leukemia with NPM1 mutation: A case report. 10, 13058-13063 ○
- 230 Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. ○
- 229 Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature. 13, ○

- 228 The Addition of Hypomethylating Agents to Low-Intensity Induction Chemotherapy Does Not Improve Outcomes in Elderly Acute Myeloid Leukemia Patients: A Single-Center Retrospective Study. **2023**, 59, 114 ○
- 227 Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML. **2023**, 55, 388-400 ○
- 226 Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation. **2023**, 14, ○
- 225 Assessment of soluble natural killer group 2d ligand (MHC Class I A and UL16 Binding Protein 1) in Iraqi patients with acute myeloid leukemia. **2022**, 21, 171 ○
- 224 Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report. **2023**, 11, ○
- 223 Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice. **2023**, 11, 2 1
- 222 At What Point Are Long-Term (>5 Years) Survivors of APL Safe? A Study from the SEER Database. **2023**, 15, 575 ○
- 221 Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment. ○
- 220 FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile. Volume 16, 31-45 ○
- 219 Early response evaluation by single cell signaling profiling in acute myeloid leukemia. **2023**, 14, 1
- 218 ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms. ○
- 217 Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. ○
- 216 High WT1 expression predicted induction chemotherapy failure in acute myeloid leukemia patients with non-favorable cytogenetic risk. ○
- 215 Development of a novel pyroptosis-related LncRNA signature with multiple significance in acute myeloid leukemia. 13, ○
- 214 A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. **2023**, 40, ○
- 213 Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. **2023**, 13, ○
- 212 Stromal Bone Marrow Fibroblasts and Mesenchymal Stem Cells Support Acute Myeloid Leukaemia Cells and Promote Therapy Resistance. ○
- 211 Impact of Disease Burden on Clinical Outcomes of AML Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.. ○

210	The RNA m6A reader YTHDF1 is required for acute myeloid leukemia progression.	0
209	An Automated Pipeline for Differential Cell Counts on Whole-Slide Bone Marrow Aspirate Smears. 2023 , 100003	0
208	Acute Myeloid Leukaemia With Translocation (8;21) Masquerading as Peripheral Blood Eosinophilia Having Dysplastic Features: A Diagnostic Challenge. 2023 ,	0
207	Galectin-9 has non-apoptotic cytotoxic activity towards Acute Myeloid Leukemia independent of cytarabine resistance.	0
206	Epigenetically silenced DACT3 promotes tumor growth via affecting Wnt/beta-catenin signaling and supports chidamide plus azacitidine therapy in acute myeloid leukemia.	0
205	CircZBTB46 Protects Acute Myeloid Leukemia Cells from Ferroptotic Cell Death by Upregulating SCD. 2023 , 15, 459	0
204	Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis. 2023 , 55, 348-360	0
203	Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia. 2023 , 15, 352	0
202	Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.	2
201	Acute myeloid leukemia: challenges for diagnosis and treatment in Latin America. 2023 , 28,	0
200	Stratification and therapeutic potential of ELL in cytogenetic normal acute myeloid leukemia. 2023 , 856, 147110	0
199	Novel high-risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53. 2023 , 272-273, 23-28	0
198	Germline Predisposition to Myeloid Neoplasms in Inherited Bone Marrow Failure Syndromes, Inherited Thrombocytopenias, Myelodysplastic Syndromes and Acute Myeloid Leukemia: Diagnosis and Progression to Malignancy. 8, 11-38	1
197	Impact of aerobic versus resistive training on functional capacity in acute myeloid leukemia survivors: a comparative study. 2021 , 21, 38-43	0
196	A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia. Publish Ahead of Print,	0
195	Roads of Drug Resistance in Acute Myeloid Leukemia: It Dead End?.	0
194	Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia: an appraisal of the new WHO and IC classifications and ELN risk stratification.	0
193	The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation. 2023 , 15, 198	0

192	Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes. 2023 , 24, 463	1
191	NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia.	0
190	A Retrospective Analysis of BCR-ABL1 Kinase Domain Mutations in the Frontline Drug Intolerant or Resistant Chronic Myeloid Leukemia Patients: An Indian Experience from a High-End Referral Laboratory.	0
189	Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis. 12,	0
188	High ME1 Expression Is a Molecular Predictor of Post-Transplant Survival of Patients with Acute Myeloid Leukemia. 2023 , 15, 296	0
187	Genomics and Diagnostics in Acute Myeloid Leukaemia. 2019 , 161-185	0
186	Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea. 2023 , 64, 123	0
185	Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group. 2023 ,	0
184	Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation.	0
183	Tumor immunology. 2023 , 245-452	0
182	Multiplex proteomics using proximity extension assay for the identification of protein biomarkers predictive of acute graft-vs.-host disease in allogeneic hematopoietic cell transplantation. 2023 ,	1
181	Lysozyme-Induced Nephropathy: A Diagnosis Not to Forget. 2023 ,	0
180	CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo. 1-12	0
179	Transplantation. 2023 , 599-674	0
178	Lipid profile as a novel prognostic predictor for patients with acute myeloid leukemia. 13,	0
177	Predicting the efficacy of BH3 mimetics through the profiling of multiple protein complexes.	0
176	Genetic Mutation Signature for Relapse Prediction in Normal Karyotype Acute Myeloid Leukemia.	0
175	SLC25A1-associated prognostic signature predicts poor survival in acute myeloid leukemia patients. 13,	0

174	Downregulation of IRAIN long non-coding RNA predicts unfavourable clinical outcome in acute myeloid leukaemia patients. 1-18	0
173	Synergistic targeting of DNA-PK and KIT signaling pathways in KIT mutant acute myeloid leukemia. 2023 , 100503	0
172	Clinical Impact of c-KIT and CEBPA Mutations in 33 Patients with Corebinding Factor (Non-M3)Acute Myeloid Leukemia. 2023 ,	0
171	The effect of granulocyte-colony stimulating factor, decitabine, and busulfan cyclophosphamide versus busulfan cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre,	0
170	Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia. 2023 , 11,	0
169	Evaluation of the HOXA9 and MEIS1 genes as a potential biomarker in adult acute myeloid leukemia. 2023 , 24,	0
168	Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. 2023 , 29, 115-126	3
167	BTYNB, an inhibitor of RNA binding protein IGF2BP1 reduces proliferation and induces differentiation of leukemic cancer cells. 2023 , 30, 103569	0
166	Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study. 13,	0
165	Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis. 2023 , 7, e846	0
164	Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.	0
163	Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML. 1-13	0
162	Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores.	0
161	Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data. 1-6	0
160	Oncogenic drivers dictate immune control of acute myeloid leukemia. 2023 , 14,	0
159	Differential effects of recombinant human thrombopoietin on clinical outcomes in CD7-positive and CD7-negative acute myeloid leukaemia. 2023 , 128, 107034	0
158	M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism. 2023 , 9,	0
157	Subclinical minute FLT3 -ITD clone can be detected in clinically FLT3 - ITD-negative acute myeloid leukaemia at diagnosis.	0

- 156 Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia. **2023**, 134, 106479 ○
- 155 MicroRNA mediated gene regulatory circuits leads to machine learning based preliminary detection of acute myeloid leukemia. **2023**, 104, 107859 ○
- 154 High expression level of the FTH1 gene is associated with poor prognosis in children with non-M3 acute myeloid leukemia. 12, ○
- 153 Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukemia - a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).. ○
- 152 Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy. **2023**, 64, 750-752 ○
- 151 New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia. **2023**, 108, 321-341 1
- 150 Leukemic stem cells and therapy resistance in acute myeloid leukemia. **2023**, 108, 353-366 ○
- 149 The clinical impact of the molecular landscape of acute myeloid leukemia. **2023**, 108, 308-320 1
- 148 Pitfalls in molecular standardization for detection of FLT3-ITD in acute myeloid leukemia. ○
- 147 Galectin-9 has non-apoptotic cytotoxic activity towards Acute Myeloid Leukemia independent of cytarabine resistance. ○
- 146 Safety and efficacy of a modified busulfan/cyclophosphamide conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation in acute myeloid leukemia. 14, ○
- 145 Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis. ○
- 144 Molecular genetics and management of world health organization defined atypical 'chronic' myeloid leukemia. **2023**, 102, 777-785 ○
- 143 Correlation of blood cell counts with mutant subtypes and impact prognosis in acute myeloid leukemia patients with FLT3 mutations. **2023**, 28, ○
- 142 Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome. **2023**, 23, ○
- 141 Combining the HCT-CI, G8, and AML-Score for Fitness Evaluation of Elderly Patients with Acute Myeloid Leukemia: A Single Center Analysis. **2023**, 15, 1002 ○
- 140 Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia. **2023**, 37, 741-750 ○
- 139 Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML. **2023**, 24, 3062 ○

- 138 Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. **2023**, 64, 846-855 ○
- 137 Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation. **2023**, 24, 3161 ○
- 136 Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis. **2023**, 102, 755-760 ○
- 135 CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. **2023**, 10, e191-e202 1
- 134 DNMT activation, TdT-aided gene length mutation, and better prognosis in ATG-based regimen allo-HSCT in AML. **2023**, 62, 665-675 ○
- 133 Mitochondrial gene expression signature predicts prognosis of pediatric acute myeloid leukemia patients. 13, ○
- 132 Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia. **2023**, 9, 519 1
- 131 Oncogenic drivers dictate immune control of acute myeloid leukemia. ○
- 130 Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis. **2023**, 102, 761-768 ○
- 129 Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2/STAT3/STAT5 axis. **2023**, 21, ○
- 128 FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia. **2023**, 16, ○
- 127 Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. **2023**, 101056 ○
- 126 Investigation of distinct gene expression profile patterns that can improve the classification of intermediate-risk prognosis in AML patients. 14, ○
- 125 Therapy-related core binding factor acute myeloid leukemia. **2023**, 12, ○
- 124 TP53 in AML and MDS: The new (old) kid on the block. **2023**, 101055 ○
- 123 Incidence and predisposing factors of infection in patients treated with hypomethylating agents. **2023**, 127, 107043 ○
- 122 Downregulation of stromal syntenin sustains AML development. ○
- 121 Microcosting Analysis of Hematopoietic Stem Cell Transplantation and Chemotherapy with Intermediate Doses of Cytarabine in the Treatment of Acute Myeloid Leukemia. ○

- 120 Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. ○
- 119 Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients. **2023**, 102, 769-775 ○
- 118 FLT3-TKD in the prognosis of patients with acute myeloid leukemia: A meta-analysis. 13, ○
- 117 CPX-351 (Vyxeos) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases. **2023**, 13, ○
- 116 Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). **2023**, 37, 799-806 ○
- 115 An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape. **2023**, 25, 369-378 ○
- 114 Targeted Therapy Development in Acute Myeloid Leukemia. **2023**, 11, 641 ○
- 113 Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation. **2023**, 15, 1312 ○
- 112 The potential role of serum extracellular vesicle derived small RNAs in AML research as non-invasive biomarker. **2023**, 5, 1691-1705 ○
- 111 Prognostication refinement in NPM1 -mutated acute myeloid leukemia stratified by FLT3 -ITD status with different induction doses of cytarabine. ○
- 110 Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review. **2023**, 15, 1362 ○
- 109 T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo. **2023**, 15, 727 ○
- 108 Genomic Alterations, Gene Expression Profiles and Functional Enrichment of Normal-Karyotype Acute Myeloid Leukaemia Based on Targeted Next-Generation Sequencing. **2023**, 15, 1386 ○
- 107 Therapeutic effect of V8 affecting mitophagy and endoplasmic reticulum stress in acute myeloid leukemia mediated by ROS and CHOP signaling. ○
- 106 ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application. **2023**, 24, ○
- 105 Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. **2023**, 37, 788-798 ○
- 104 Machine learning investigation of gene expression datasets reveals TP53 mutant-like AML with wild type TP53 and poor prognosis. ○
- 103 Albumin-to-Fibrinogen Ratio is an Independent Prognostic Parameter in De Novo non-M3 acute myeloid leukemia. ○

102	Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine: A Prospective Cohort Study by the AGMT. 2023 , 15, 1388	0
101	Evolving Risk Classifications in AML in a Real-Life Scenario: After Changes upon Changes, Is It More and More Adverse?. 2023 , 15, 1425	0
100	Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia.	0
99	Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience. 2023 , 77, 101808	0
98	Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC. 2023 ,	0
97	The Heterogeneous Complexity of Myeloid Neoplasm: Multi-Level Approaches to Study the Disease. 2023 , 15, 1449	0
96	Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia. 2023 , 12,	1
95	Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes. 2023 , 8,	1
94	Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia. 2023 , 43, 328-336	1
93	Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia.	0
92	Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.	0
91	Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Therapy-Related Acute Myeloid Leukemia: a Retrospective Multicentre Study on behalf of the SFGM-TC.	0
90	Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. 2023 , 98, 760-769	1
89	Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies. 2023 , 91, 281-290	0
88	The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience. 2023 , 59, 498	0
87	Secondary acute lymphoblastic/lymphocytic leukemia - done playing second fiddle?. 2023 , 101070	0
86	Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study. 2023 , 15, 1609	0
85	Prospective Identification of Prognostic Hot-Spot Mutant Gene Signatures for Leukemia: A Computational Study Based on Integrative Analysis of TCGA and cBioPortal Data.	0

- 84 Assessing eligibility for treatment in acute myeloid leukemia in 2023. **2023**, 16, 181-190 ○
- 83 Characterization of bone marrow heterogeneity in NK-AML (M4/M5) based on single-cell RNA sequencing. **2023**, 12, ○
- 82 Heterogeneity analysis of the CEBPAdm AML based on bZIP region mutations. Publish Ahead of Print, ○
- 81 Phase I Clinical Trial. Safety of Baricitinib to prevent respiratory insufficiency in oncohematological patients affected by Coronavirus Disease-19: BARCOVID19 study. ○
- 80 Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia. 14, ○
- 79 DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. **2023**, 329, 745 ○
- 78 Swollen gums in a young adult. o2492 ○
- 77 Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents. 1-7 ○
- 76 A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia. ○
- 75 TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia. **2023**, ○
- 74 A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia. **2023**, 15, 1666 ○
- 73 Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). ○
- 72 Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms. 1-3 ○
- 71 CD27+ microparticle interactions and immunoregulation of CD4+ T lymphocytes. 14, ○
- 70 Acute myeloid leukemia: Incidence, transplantation and survival through Italian administrative healthcare data. 030089162311536 ○
- 69 The occurrence of thrombosis during intensive chemotherapy treatment for acute myeloid leukemia patients does not impact on long-term survival. **2023**, 102, 1037-1043 ○
- 68 Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). **2023**, 13, ○
- 67 RNA sequencing of myeloid sarcoma, shed light on myeloid sarcoma stratification. ○

- 66 The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. **2023**, 615, 920-924 ○
- 65 Validation of National Early Warning Score and Quick Sequential (sepsis-related) Organ Failure Assessment in acute myeloid leukaemia patients treated with intensive chemotherapy. ○
- 64 Explainable AI identifies diagnostic cells of genetic AML subtypes. **2023**, 2, e0000187 ○
- 63 Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients. **2023**, 11, ○
- 62 Combination of hypomethylating agents and inhibitor of BCL-2 in treatment of patients with relapsed acute myeloid leukemia: S.P. Botkin hospital experience. **2023**, 18, 12-19 ○
- 61 Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. ○
- 60 Sustained spontaneous remission in KMT2A-MLLT3 mutated myeloid sarcoma. **2023**, 102, 1271-1274 ○
- 59 Quality of Life, Physical Functioning, and Psychological Distress of Older Adults Undergoing Hematopoietic Stem Cell Transplantation. **2023**, ○
- 58 Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience. **2023**, 102, 1045-1052 ○
- 57 Identifying prognostic gene panels in acute myeloid leukemia. **2023**, 16, 277-287 ○
- 56 Variation in Lipid Species Profiles among Leukemic Cells Significantly Impacts Their Sensitivity to the Drug Targeting of Lipid Metabolism and the Prognosis of AML Patients. **2023**, 24, 5988 ○
- 55 An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment. **2023**, 24, 6031 ○
- 54 Does leukocytosis remain a predictive factor for survival outcomes in patients with acute promyelocytic leukemia receiving ATRA plus a chemotherapy-based regimen? A prospective multicenter analysis from TALWG. **2023**, 28, ○
- 53 The Microbiome and Its Impact on Allogeneic Hematopoietic Cell Transplantation. **2023**, 29, 75-83 ○
- 52 Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT. 13, ○
- 51 Recent advances in targeted therapies in acute myeloid leukemia. **2023**, 16, ○
- 50 RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia. 1-11 ○
- 49 Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome. **2023**, ○

- 48 Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein. **2023**, 9, ○
- 47 Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia. **2023**, 14, ○
- 46 RNA demethylase ALKBH5 promotes tumorigenesis of t (8;21) acute myeloid leukemia via ITPA m6A modification. **2023**, 11, ○
- 45 Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia. 13, ○
- 44 The expression level of ARF and p53 in AML patients, and their relation to patients' outcome. **2023**, 24, ○
- 43 Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia. **2023**, 15, ○
- 42 Efficacy and feasibility of Pharmacoscopy-guided treatment for acute myeloid leukemia patients that exhausted all registered therapeutic options. ○
- 41 Status of FLT3-ITD Analysis in Korea (2021). **2023**, 13, 72-77 ○
- 40 HLA Class I genotype is associated with relapse risk after allogeneic stem cell transplantation for NPM1-mutated AML. **2023**, ○
- 39 A novel scoring system for the quantitative prediction of prognosis in acute myeloid leukemia. 13, ○
- 38 Consensus for Flow Cytometry Clinical Report on Multiple Myeloma: A Multicenter Harmonization Process Merging Laboratory Experience and Clinical Needs. **2023**, 15, 2060 ○
- 37 Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML -001 trial. ○
- 36 The clinical impact of IKZF1 mutation in acute myeloid leukemia. **2023**, 12, ○
- 35 Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. ○
- 34 The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study. ○
- 33 Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group. **2023**, 9, e14924 ○
- 32 Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice. ○
- 31 The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease. ○

- 30 The FLT3-ITD allelic ratio and NPM1 mutation do not impact outcomes in AML patients with FLT3-ITD after allo-HSCT: a retrospective propensity-score matching study. **2023,** ○
- 29 Place des outils moléculaires dans les leucémies aiguës myéloïdes en 2023. **2023, 2023, 52-63** ○
- 28 Actualité des classifications des leucémies aiguës myéloïdes. **2023, 2023, 22-33** ○
- 27 Diagnostic et prise en charge des prédispositions génétiques aux hémopathies malignes. **2023, 2023, 34-39** ○
- 26 Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemia. ○
- 25 Updates in molecular genetics of acute myeloid leukemia. **2023,** ○
- 24 Combating breast cancer progression through combination therapy with hypomethylating agent and glucocorticoid. **2023, 26, 106597** ○
- 23 The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis. **2023, 28,** ○
- 22 Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. ○
- 21 Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier. **2023, 21,** ○
- 20 Outcome of patients with newly diagnosed AML admitted to the ICU, including preemptive admission in a multi-center study. ○
- 19 The effect of the time from diagnosis to induction therapy on prognosis in patients with acute leukemia undergoing leukapheresis for symptomatic hyperleukocytosis. ○
- 18 Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. ○
- 17 Therapy-related myeloid neoplasms after ¹⁷⁷Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategy. 1-3 ○
- 16 Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. ○
- 15 What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. **2023, 15, 2248** ○
- 14 Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia. **2023, 15, 2267** ○
- 13 Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group. **2023, 15, 2305** ○

- 12 Incidence of invasive infections among hemato-oncology patients with significant burden of Candida in stool. ○
- 11 Primary hemostasis dysfunctions and bleeding risk in newly diagnosed acute myeloid leukemia. ○
- 10 Myeloid Sarcoma: An Overview.. **2023**, ○
- 9 Identification and validation of a novel CD8+ T cell-associated prognostic model based on ferroptosis in acute myeloid leukemia. 14, ○
- 8 Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia. 1-7 ○
- 7 A novel risk model for predicting early relapse in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem-cell transplantation. ○
- 6 Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group. ○
- 5 Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience. ○
- 4 Financial toxicity in patients with leukemia undergoing hematopoietic stem cell transplantation: A systematic review. **2023**, 36, 101469 ○
- 3 Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial. **2023**, 7, e877 ○
- 2 Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connecticut Myeloid Disease Registry: Potential Barriers to Care. **2023**, ○
- 1 Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia [a single center experience] ○